Innovation1 Biotech (IVBT) S-1 15 Feb 22 IPO registration Financial data

Cover

Cover	3 Months Ended
	Nov. 30, 2021
Cover [Abstract]
Entity Registrant Name	GRIDIRON BIONUTRIENTS, INC.
Entity Central Index Key	0001629205
Document Type	S-1
Amendment Flag	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Tax Identification Number	82-2275255
Entity Address Address Line 1	40 Wall Street
Entity Address Address Line 2	Suite 2701
Entity Address City Or Town	New York
Entity Address State Or Province	NY
Entity Address Postal Zip Code	10005
City Area Code	646
Local Phone Number	380-1923
Entity Incorporation State Country Code	NV

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Current assets:
Cash	$ 2,933,712	$ 137,476	$ 17,881
Inventory	0	17,000	37,450
Prepaid expenses	15,450	14,000	13,945
Notes receivable, net of discount		0	132,852
Total current assets	2,949,162	168,476	202,128
Other assets
Equity investment, net of discount	0	11,132	2,783
Equipment, net of accumulated depreciation of $4,558 and $3,144, respectively	0	598	2,012
Trademarks	1,680	1,680	1,680
Intangibles	81,427,827
Total other assets	81,429,507	13,410	6,475
Total Assets	84,378,669	181,886	208,603
Current liabilities:
Accounts payable	437,041
Accrued expenses	103,298
Mioxal liability	28,500,000
Accounts payable and accrued expenses		43,930	443,496
Related party payable	0	64,600	73,469
Derivative liability	0	0	1,454,480
Note payable, current portion	10,000	160,000	10,000
Note payable, convertible net of discount		0	831,170
Dividends payable	275,082	138,195	73,995
Total current liabilities	29,325,421	406,725	2,886,610
Long term liabilities:
Mioxal liability	11,000,000
Total long term liabilities	11,000,000
Total liabilities	40,325,421	406,725	2,886,610
Commitments and contingencies	0	0	0
Stockholders' equity (deficiency):
Common stock, $0.001 par value; 200,000,000 shares authorized; 188,616 and 187,194 shares issued and outstanding as of August 31, 2021 and 2020, respectively	20,020	188	187
Additional paid in capital	47,375,512	2,745,906	1,157,253
Accumulated deficit	(3,350,368)	(2,973,628)	(3,843,927)
Total stockholders' equity (deficiency)	44,053,248	(224,839)	(2,678,007)
Total Liabilities and Stockholders' equity	84,378,669	181,886	208,603
Preferred stock Series A [Member]
Stockholders' equity (deficiency):
Preferred stock value	0	0	8,480
Preferred stock Series B [Member]
Stockholders' equity (deficiency):
Preferred stock value	$ 8,084	$ 2,695	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Other assets
Accumulated depreciation	$ 0	$ 4,558	$ 3,144
Stockholders' equity
Common stock, shares outstanding	20,020,239	188,616	187,194
Common stock , shares par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued	20,020,239	188,616	187,194
Common stock, shares authorized	200,000,000	200,000,000	200,000,000
Preferred stock Series A [Member]
Stockholders' equity
Preferred stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	22,305,486	22,305,486	22,305,486
Preferred stock, shares issued	0	0	8,480,000
Preferred stock, shares outstanding	0	0	8,480,000
Preferred stock Series B [Member]
Stockholders' equity
Preferred stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	8,083,542	8,083,542	2,694,514
Preferred stock, shares issued	8,083,542	2,694,514	0
Preferred stock, shares outstanding	8,083,542	2,694,514	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 0	$ 3,080	$ 3,080	$ 1,181
Cost of Revenue	0	1,421	1,421	2,964
Gross margin	0	1,659	1,659	(1,783)
Operating expenses:
Advertising	156	210	677	2,664
Consulting fees	138,330	15,000	73,375	63,375
General and administrative	12,464	12,003	49,184	85,637
Professional fees	108,931	31,621	117,414	63,418
Salaries	101,191	0
Total operating expenses	361,072	58,834	240,650	215,094
Net operating income (loss)	(361,072)	(57,175)	(238,991)	(216,877)
Other (income) expense:
Interest expense	5,139	36,750	105,424	427,286
Interest income	0	(27,724)	(55,567)	(41,246)
Impairment expense	17,598	0	19,450	587,623
Expenses related to convertible notes payable and preferred warrants:
(Gain) loss on change in fair value of derivative liability	0	92,642	(1,454,480)	(301,581)
Interest accretion	0	80,512	114,599	869,967
Gain on extinguishment of debt	(143,956)	0
Debt/Equity issuance costs on convertible notes payable			0	861,680
Other (income) expense	0	(2,087)	(8,349)	(40,538)
Total Other (income) expense	(121,219)	180,093	(1,278,923)	2,363,191
Net income (loss)	$ (239,853)	$ (237,268)	$ 1,039,932	$ (2,580,068)
Basic income (loss) per shares	$ (0.04)	$ (1.27)	$ 5.53	$ (8.59)
Weighted average number of common shares outstanding - basic	5,636,864	187,194	188,094	300,323

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Series A, Preferred Stock	Series B, Preferred Stock	Common Stock	Additional Paid-In Capital	Common Stock to be Issued [Member]	Accumulated Deficit
Balance, shares at Aug. 31, 2019		8,480,000		439,285
Balance, amount at Aug. 31, 2019	$ 32,361	$ 8,480	$ 0	$ 439	$ 1,077,001	$ 160,000	$ (1,213,559)
Issuance of common stock for stock subscription, shares				742
Issuance of common stock for stock subscription, amount	0	0	0	$ 1	159,999	(160,000)
Repurchase and retirement of common stock, shares				(252,833)
Repurchase and retirement of common stock, amount	(80,000)	0	0	$ (253)	(79,747)	0	0
Dividends on preferred stock accrued	(50,300)	0	0	0	0	0	(50,300)
Net income (loss)	(2,580,068)	$ 0	0	$ 0	0	0	(2,580,068)
Balance, shares at Aug. 31, 2020		8,480,000		187,194
Balance, amount at Aug. 31, 2020	(2,678,007)	$ 8,480	0	$ 187	1,157,253	0	(3,843,927)
Dividends on preferred stock accrued	(12,575)	0	0	0	0		(12,575)
Net income (loss)	(237,268)	$ 0	0	$ 0	0		(237,268)
Balance, shares at Nov. 30, 2020		8,480,000		187,194
Balance, amount at Nov. 30, 2020	(2,927,850)	$ 8,480	0	$ 187	1,157,253		(4,093,770)
Balance, shares at Aug. 31, 2020		8,480,000		187,194
Balance, amount at Aug. 31, 2020	(2,678,007)	$ 8,480	0	$ 187	1,157,253	0	(3,843,927)
Dividends on preferred stock accrued	(169,633)	0	0	0	0	0	(169,633)
Net income (loss)	1,039,932	$ 0	$ 0	0	0	0	1,039,932
Exchange agreement - conversion of preferred stock, shares		(8,480,000)	2,694,514
Exchange agreement - conversion of preferred stock, amount	1,582,869	$ (8,480)	$ 2,695	$ 0	1,588,654	0	0
Adjustment for reverse split, shares				1,422
Adjustment for reverse split, amount	0	0	$ 0	$ 1	(1)	0	0
Balance, shares at Aug. 31, 2021			2,694,514	188,616
Balance, amount at Aug. 31, 2021	(224,839)	0	$ 2,695	$ 188	2,745,906	$ 0	(2,973,628)
Dividends on preferred stock accrued	(136,887)	0	$ 0	0			(136,887)
Net income (loss)	(239,853)						(239,853)
Series B-1 preferred stock purchase agreements, shares			5,389,028
Series B-1 preferred stock purchase agreements, amount	4,000,000	0	$ 5,389	$ 0	3,994,611		0
Common Stock issued for asset purchase, shares				19,831,623
Common Stock issued for asset purchase, amount	40,654,827	$ 0	$ 0	$ 19,832	40,634,995		0
Balance, shares at Nov. 30, 2021			8,083,542	20,020,239
Balance, amount at Nov. 30, 2021	$ 44,053,248		$ 8,084	$ 20,020	$ 47,375,512		$ (3,350,368)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020
CONSOLIDATED STATEMENTS OF CASH FLOW
Net income (loss)	$ (239,853)	$ (237,268)	$ 1,039,932	$ (2,580,068)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	0	430	1,414	2,613
Debt/stock based issue costs			0	(301,581)
(Gain) Loss on change in fair value of derivative liability	0	173,154	(1,454,480)	1,731,647
Interest accretion			114,599	0
Impairment expense	17,598	0	19,450	76,960
Prior year correction to note payable, current portion (See Note 6)			0	(39,500)
Gain on extinguishment of debt	(143,956)	0
Realized income on investment	0	(2,087)	(8,349)	(2,783)
Changes in operating assets and liabilities:
Accounts receivable	0	(3,080)
Inventory	0	1,000	1,000	166,113
Prepaid expenses	(1,450)	4,945	(55)	11,666
Notes receivable	0	28,820	132,852	67,148
Accounts payable and accrued expenses			132,101	422,517
Accounts Payable	(22,745)	45,529
Accrued expenses	101,242	0
Related party payable	(64,600)	226	(8,869)	35,020
Net cash provided by (used in) operating activities	(353,764)	11,669	(30,405)	(410,248)
Cash flows from investing activities:
Repurchase and retirement of common stock				(80,000)
Cash paid for asset purchase	(350,000)	0
Notes receivable investment	(500,000)	0	0	(300,000)
Net cash used in investing activities	(850,000)	0	0	(380,000)
Cash flows from financing activities
Proceeds from convertible notes payable			0	828,000
Proceeds from notes payable			150,000	0
Repayment of convertible notes payable				(38,846)
Proceeds form series B-1 preferred stock purchase agreements	4,000,000	0
Net cash provided by financing activities	4,000,000	0	150,000	789,154
Net increase (decrease) in cash	2,796,236	11,669	119,595	(1,094)
Cash - beginning of the year	137,476	17,881	17,881	18,975
Cash - end of the year	2,933,712	29,550	137,476	17,881
Supplemental disclosures:
Interest paid	0	0	0	0
Income taxes	0	0	0	0
Non-cash transactions:
Preferred stock dividends accrued	136,887	12,575	169,633	50,300
Discount on convertible note payable			0	129,615
Issuance of common stock from shares to be issued	$ 40,654,827	$ 0	$ 0	$ 160,000

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
ORGANIZATION AND DESCRIPTION OF BUSINESS
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Gridiron BioNutrients, Inc. (the “Company” or “Gridiron”) was formed under the laws of the state of Nevada on July 20, 2017 to develop and distribute a retail line of health water infused with probiotics and minerals. The Company has acquired five proprietary preclinical prodrugs, all fully synthetic without connection to botanical sourcing: a mushroom-derived psychedelic molecule for treatment post-traumatic stress disorder and depression, a novel cannabinoid for treatment of addiction and three additional novel cannabinoid prodrugs addressing clinical indications of refractory epilepsy, burn wounds and uveitis. The Company also owns a patented nutraceutical complex specially designed and formulated to contribute and help maintain normal energy metabolism, improve mood and reduce fatigue for those suffering from fibromyalgia and chronic fatigue syndrome. The Company has elected an August 31 st On December 22, 2020, the Company filed Articles of Amendment to its Articles of Incorporation, as amended, which were effective on January 8, 2021 (the “Effective Date”), which effected a three hundred eight for one (308:1) reverse stock split of its outstanding common stock. Previously, on December 4, 2020 the Company filed a definitive Information Statement on Schedule 14C with the SEC notifying its stockholders that on December 2, 2020, the holders of a majority of its outstanding shares of common stock and the shares Series A Convertible Preferred Stock who were entitled to consent to the action, voting as a single class, executed a written consent in lieu of a special meeting of stockholders approving a reverse stock split of the Company’s outstanding common stock of not less than 300:1 and not more than 310:1, with the Company’s board of directors having the discretion as to when such reverse stock split would be effected (on or prior to December 2, 2021) and the exact ratio of the reverse stock split to be set at a whole number within the above range as determined by the board of directors in its sole discretion. On December 17, 2020, in accordance with such authority, the board of directors fixed the exact ratio of the reverse stock split. Change in Control On November 9, 2021, the Company completed the acquisition of all of the assets, including intellectual property assets, relating to Mioxal® as discussed in Note 4 - Asset Purchase.	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Gridiron BioNutrients, Inc. (the “Company” or “Gridiron”) was formed under the laws of the state of Nevada on July 20, 2017 to develop and distribute a retail line of health water infused with probiotics and minerals. The Company is currently developing products which contain a proprietary blend of humic and fulvic acid, trace minerals, probiotics, electrolytes, cannabidiol (CBD) within an alkaline of pH10. Gridiron has secured the rights to this proprietary formulation through its CEO, Timothy Orr (Verbal Agreement). Timothy Orr provided the formulation in connection with his receipt of 105,519shares of common stock from the Company on October 9, 2017. Gridiron has the exclusive right(s) to develop CBD products with this formulation. However, Gridiron is limited to developing only CBD products with this formulation and as such does not have any rights to develop products that do not contain CBD with this formulation. The Company has elected an August 31 st On December 22, 2020, the Company filed Articles of Amendment to its Articles of Incorporation, as amended, which were effective on January 8, 2021 (the “Effective Date”), which effected a three hundred eight for one (308:1) reverse stock split of its outstanding common stock. Previously, on December 4, 2020 the Company filed a definitive Information Statement on Schedule 14C with the SEC notifying its stockholders that on December 2, 2020, the holders of a majority of its outstanding shares of common stock and the shares Series A Convertible Preferred Stock who were entitled to consent to the action, voting as a single class, executed a written consent in lieu of a special meeting of stockholders approving a reverse stock split of the Company’s outstanding common stock of not less than 300:1 and not more than 310:1, with the Company’s board of directors having the discretion as to when such reverse stock split would be effected (on or prior to December 2, 2021) and the exact ratio of the reverse stock split to be set at a whole number within the above range as determined by the board of directors in its sole discretion. On December 17, 2020, in accordance with such authority, the board of directors fixed the exact ratio of the reverse stock split. Acquisition and Reverse Merger On October 10, 2017, the Company completed a reverse merger with My Cloudz, Inc. (“My Cloudz”) pursuant to which the Company merged into My Cloudz on October 10, 2017. Under the terms of the merger, the Company shareholders received 227,273common shares of My Cloudz common stock such that the Company shareholders received approximately 57% of the total common shares issued and outstanding following the merger. Due to the nominal assets and limited operations of My Cloudz prior to the merger, the transaction was accorded reverse recapitalization accounting treatment under the provision of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 805 whereby the Company became the accounting acquirer (legal acquiree) and My Cloudz was treated as the accounting acquiree (legal acquirer). The historical financial records of the Company are those of the accounting acquirer (GridIron) adjusted to reflect the legal capital of the accounting acquiree (My Cloudz). As the transaction was treated as a recapitalization, no intangibles, including goodwill, were recognized. Concurrent with the effective date of the reverse recapitalization transaction, the Company adopted the fiscal year end of the accounting acquirer of August 31. At the date of acquisition, My Cloudz had $3,972 of cash, $1,105 of accounts payable and a related party payable of $75,907. Book values for all assets acquired and liabilities assumed equaled fair values as of the date of acquisition.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation This summary of accounting policies for Gridiron is presented to assist in understanding the Company’s financial statements. The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting) and have been consistently applied in the preparation of the financial statements. Reclassifications Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. Estimates are used when accounting for fair value calculations related to embedded conversion features of outstanding convertible notes payable. As discussed on Note 4 - Exchange Agreement Cash For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. The Company had $2,933,712 and $137,476 of cash as of November 30, 2021 and August 31, 2021, respectively. The 2,976,236increase was from our Series B-1 stock subscriptions as discussed in Note 9 - Stockholders’ Equity. Revenue recognition Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. Fair Value of Financial Instruments Fair value of certain of the Company’s financial instruments including cash, prepaid expenses, accounts payable, accrued expenses, notes payable, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value investments. Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of income. As discussed in Note 11 - Derivative Liability, Note 4 - Exchange Agreement Derivative Liabilities The Company generally does not use derivative financial instruments to hedge exposures to cash flow or market risks. However, certain other financial instruments, such as warrants and embedded conversion features on the convertible debt, are classified as derivative liabilities due to protection provisions within the agreements. Convertible notes payable are initially recorded at fair value using the Monte Carlo model and subsequently adjusted to fair value at the close of each reporting period. The preferred stock warrants are initially recorded at fair value using the Black Scholes model and subsequently adjusted to fair value at the close of each reporting period. The Company accounts for derivative instruments and debt instruments in accordance with the interpretive guidance of ASC 815, ASU 2017-11, and associated pronouncements related to the classification and measurement of warrants and instruments with conversion features. Income Taxes Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Use of net operating loss carry forwards for income tax purposes may be limited by Internal Revenue Code section 382 if a change of ownership occurs. Principals of Consolidation The consolidated financial statements represent the results of Gridiron BioNutrients, Inc, its wholly owned subsidiary, Gridiron Ventures and the assets, processes, and results therefrom. All intercompany transactions and balances have been eliminated. All financial information has been prepared in conformity with accounting principles generally accepted in the United States of America. Property and Equipment Property and equipment are carried at cost. Expenditures for maintenance and repairs are expensed in the period incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed for financial statement purposes on a straight-line basis over estimated useful lives of the related assets and the modified accelerated cost recovery system for federal income tax purposes. The estimated useful lives of depreciable assets are: Estimated Useful Lives Computer and other equipment 3 years Vehicle 5 years The Company’s property and equipment consisted of the following as of November 30, 2021 and August 31, 2021: November 30, 2021 August 31, 2021 Computer Equipment $ -0- $ 1,569 Other -0- 3,587 Accumulated depreciation -0- (4,558 ) Net book value $ -0- $ 598 With the asset acquisition as discussed in Note 3 - Asset Acquisition Inventories Inventories consist of raw materials and T-free distillate and are stated at the lower of cost or net realizable value using the first‑in, first‑out method. The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write‑downs for excess, defective and obsolete inventory are recorded as impairment expense in the accompanying statement of operations. The Company wrote-off $17,000and $-0- of obsolete inventory or inventory below market value for the for the three months ended November 30, 2021 and 2020, respectively. A summary of the Company’s inventory as of November 30, 2021 and August 31, 2021 are as follows: Type November 30, 2021 August 31, 2021 Raw Materials $ -0- $ -0- T-free Distillate -0- 17,000 Total Inventory $ -0- $ 17,000 Basic Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. The Series B and Series B1 Convertible Preferred shares would convert to 8,083,542 shares of the Company’s common stock in addition to the 20,020,239 outstanding shares at November 30, 2021. The Company calculates diluted earnings per share by dividing the Company’s net income available to common shareholders less preferred dividends by the diluted weighted average number of shares outstanding during the period. The conversion of the Company’s Series B and Series B1 Convertible Preferred shares are excluded from the computation of diluted earnings per share as they are anti-dilutive due to the Company’s operating losses for the three months ended November 30, 2021 and 2020. Dividends During the year ended August 31, 2018, the Company issued Series A Convertible Preferred Stock, which accrues dividends at a rate of 5% annually. As discussed on Note 4 - Exchange Agreement Advertising Costs The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising costs totaling $156 and $210 during the three months ended November 30, 2021 and 2020, respectively. Stock-Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. There was $-0- stock-based compensation during three months ended November 30, 2021 and 2020. Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06 , Derivatives and Hedging Derivatives and Hedging-Contracts in Entity’s Own Equity Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company. Accounts Receivable Accounts receivable balances are established for amounts owed to the Company from its customers from the sale of products. The Company closely monitors the collectability of outstanding accounts receivable and provide an allowance for doubtful accounts based on estimated collections of outstanding amounts. The Company evaluated the accounts receivable and determined no collection loss reserve was necessary. There were $-0- outstanding accounts receivable as of November 30, 2021 and August 31, 2021. Trademark Trademark costs are capitalized as incurred to the extent the Company expects the costs incurred to result in a trademark being awarded. The trademarks are deemed to have an indefinite life and are reviewed for impairment loss considerations annually. As of November 30, 2021 and August 31, 2021, the Company had trademarks totaling $1,680.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation This summary of accounting policies for Gridiron is presented to assist in understanding the Company’s financial statements. The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting) and have been consistently applied in the preparation of the financial statements. Reclassifications Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. Estimates are used when accounting for fair value calculations related to embedded conversion features of outstanding convertible notes payable. As discussed on Note 3 – Exchange Agreement Cash For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. The Company had $137,476 and $17,881 of cash as of August 31, 2021 and 2020, respectively. Revenue recognition Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. Fair Value of Financial Instruments Fair value of certain of the Company’s financial instruments including cash, prepaid expenses, accounts payable, accrued expenses, notes payable, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value investments. Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of income. As discussed in Note 10 – Derivative Liability, Note 3 – Exchange Agreement Derivative Liabilities The Company generally does not use derivative financial instruments to hedge exposures to cash flow or market risks. However, certain other financial instruments, such as warrants and embedded conversion features on the convertible debt, are classified as derivative liabilities due to protection provisions within the agreements. Convertible notes payable are initially recorded at fair value using the Monte Carlo model and subsequently adjusted to fair value at the close of each reporting period. The preferred stock warrants are initially recorded at fair value using the Black Scholes model and subsequently adjusted to fair value at the close of each reporting period. The Company accounts for derivative instruments and debt instruments in accordance with the interpretive guidance of ASC 815, ASU 2017-11, and associated pronouncements related to the classification and measurement of warrants and instruments with conversion features. Income Taxes Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Use of net operating loss carry forwards for income tax purposes may be limited by Internal Revenue Code section 382 if a change of ownership occurs. Principals of Consolidation The consolidated financial statements represent the results of Gridiron BioNutrients, Inc, its wholly owned subsidiary, Gridiron Ventures and the assets, processes, and results therefrom. All intercompany transactions and balances have been eliminated. All financial information has been prepared in conformity with accounting principles generally accepted in the United States of America. Property and Equipment Property and equipment are carried at cost. Expenditures for maintenance and repairs are expensed in the period incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed for financial statement purposes on a straight-line basis over estimated useful lives of the related assets and the modified accelerated cost recovery system for federal income tax purposes. The estimated useful lives of depreciable assets are: Estimated Useful Lives Computer and other equipment 3 years Vehicle 5 years The Company’s property and equipment consisted of the following as of August 31, 2021 and 2020: August 31, 2021 August 31, 2020 Computer Equipment $ 1,569 $ 1,569 Other 3,587 3,587 Accumulated depreciation (4,558 ) (3,144 ) Net book value $ 598 $ 2,012 Depreciation expense was $1,414 and $2,613 for the years ended August 31, 2021 and 2020, respectively. Inventories Inventories consist of raw materials and T-free distillate and are stated at the lower of cost or net realizable value using the first‑in, first‑out method. The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write‑downs for excess, defective and obsolete inventory are recorded as impairment expense in the accompanying statement of operations. The Company wrote-off $19,450 and $485,662 of obsolete inventory or inventory below market value for the for the years ended August 31, 2021 and 2020, respectively. A summary of the Company’s inventory as of August 31, 2021 and 2020 are as follows: Type August 31, 2021 August 31, 2020 Raw Materials $ -0- $ 450 T-free Distillate 17,000 37,000 Total Inventory $ 17,000 $ 37,450 Basic Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. The Series B Convertible Preferred shares would convert to 2,694,514 shares of the Company’s common stock in addition to the 188,616 outstanding shares at August 31, 2021. The Company calculates diluted earnings per share by dividing the Company’s net income available to common shareholders less preferred dividends by the diluted weighted average number of shares outstanding during the period. The conversion of the Company’s Series B Convertible Preferred shares are excluded from the computation of diluted earnings per share as they are anti-dilutive due to the Company’s operating losses for the years ended August 31, 2021 and 2020. Dividends During the year ended August 31, 2018, the Company issued Series A Convertible Preferred Stock, which accrues dividends at a rate of 5% annually. As discussed on Note 3 – Exchange Agreement Advertising Costs The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising costs totaling $677 and $2,664 during the years ended August 31, 2021 and 2020, respectively. Stock-Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. There was $-0- stock-based compensation during years ended August 31, 2021 and 2020. Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06 , Derivatives and Hedging Derivatives and Hedging—Contracts in Entity’s Own Equity Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company. Accounts Receivable Accounts receivable balances are established for amounts owed to the Company from its customers from the sale of products. The Company closely monitors the collectability of outstanding accounts receivable and provide an allowance for doubtful accounts based on estimated collections of outstanding amounts. The Company evaluated the accounts receivable and determined no collection loss reserve was necessary. There were $-0- outstanding accounts receivable as of August 31, 2021 and 2020. Trademark Trademark costs are capitalized as incurred to the extent the Company expects the costs incurred to result in a trademark being awarded. The trademarks are deemed to have an indefinite life and are reviewed for impairment loss considerations annually. As of August 31, 2021 and 2020, the Company had trademarks totaling $1,680.

ASSET ACQUISITION

ASSET ACQUISITION	3 Months Ended
	Nov. 30, 2021
ASSET ACQUISITION
ASSET ACQUISITION	NOTE 3 - ASSET ACQUISITION On November 9, 2021, the Company completed the acquisition (the “Acquisition”) of all of the assets, including intellectual property assets, relating to Mioxal®, a nutraceutical complex composed of essential amino acids, natural coenzymes and minerals, and assumed certain liabilities held by ST BioSciences, Ltd., a company organized under the laws of England and Wales (“STB”). The Acquisition was completed pursuant to the terms of the Amended and Restated Asset Purchase Agreement dated November 5, 2021. As consideration for the Acquisition, the Company paid $350,000 cash and issued 19,831,623 shares of Common Stock to STB valued at $40,654,827 or $2.05 per share based on the closing market price on November 5, 2021, which at the closing of the acquisition represented approximately 70% of the Company’s outstanding shares of Common Stock on a fully diluted basis. The aggregate fair value of the Acquisition was $41,004,827. In addition, as a result of the consummation of the Acquisitiona convertible promissory note payable to the Company for $500,000 by STB was canceled and netted against the Company’s associated convertible promissory note receivable. See Note 6 - Notes Receivable The Mioxal® asset was acquired by STB from Ingenius Biotech S.L, a Spain corporation (“Ingenius”) on September 10, 2021. Ingenius manages the Mioxal® asset. The Ingenius milestone and stock payments were assumed by the Company in aggregate of $39,500,000 and are recorded in current and long-term liabilities in the accompanying consolidated balance sheets. Upon meeting the milestones, the first installment of $1,500,000 is due on January 15, 2022, the second installment of $1,500,000 on April 15, 2022 and $3,500,000 thereafter for each milestone event for an aggregate of $24,500,000. If the first milestone event does not occur on or before January 15, 2022, then the milestone payment will be forfeited and never owed. The milestone being a signed sales agreement with a third party to distribute Mioxal throughout Europe. In addition, Ingenius will receive three tranches of the Company’s common stock beginning twelve months from execution of agreement with STB on September 10, 2021, as follows: · On September 10, 2022 - $4,000,000 · On September 10, 2023 - $5,000,000 · On September 10, 2024 - $6,000,000 · Total stock to be issued - $15,000,000 In addition, until the $39,500,000 is paid in cash and the Company’s common stock, Ingenius will earn an 8% royalty on all sales generated by Mioxal®. An additional $423,000 of STB liabilities were assumed by the Company on November 9, 2021. The assets and liabilities assumed has been valuated at the fair values as follows: Mioxal® $ 81,249,827 Other intangible assets 178,000 Less liabilities assumed: Mioxal® liability assumed 39,500,000 Other liabilities assumed 423,000 Convertible note payable to the Company 500,000 Net fair value acquired in asset acquisition $ 41,004,827 The Mioxal® asset is under development and will be amortized over the useful life of 24 years in subsequent periods with an annual amortization for $3,385,409. The other intangible assets for $178,000 are under development and will be amortized over the useful life of 21 years in subsequent periods with an annual amortization for $8,476. All intangible assets will be tested for impairment on an annual basis or sooner if deemed necessary. During January 2022, the 19,831,623 shares acquired by STB in the Acquisition were distributed to STB shareholders as a dividend.

EXCHANGE AGREEMENT

EXCHANGE AGREEMENT	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
EXCHANGE AGREEMENT
NOTE 3 - EXCHANGE AGREEMENT	NOTE 4 - EXCHANGE AGREEMENT On April 9, 2021 Company entered into an Exchange Agreement with Calvary Fund Management, LLC (“Calvary”) pursuant to which it agreed to issue Calvary 2,694,514 shares of its newly designated Series B Convertible Preferred Stock (the “Series B Preferred”) in exchange (the “Exchange”) for (i) 8,480,000 shares of its Series A Convertible Preferred Stock (the “Series A Preferred”), (ii) outstanding common stock purchase warrants (the “Warrants”), and (iii) all principal and accrued interest due under outstanding convertible promissory notes (the “Convertible Notes”, and together with the Series A Preferred and the Warrants, the “Calvary Securities”). The closing of the Exchange (the “Closing”) will occur following the satisfaction or waiver of the conditions set forth in the Exchange Agreement. On the Closing date, subject to the terms and conditions of the Exchange Agreement, the Company will issue the Series B Preferred to Calvary in exchange for the Calvary Securities (which will be cancelled and retired) in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on exemptions provided pursuant to Section 3(a)(9) of the Securities Act. The Series B Preferred Designations designated 2,694,514 shares of the Company’s blank check preferred stock as Series B Preferred Stock. In addition to rights granted to holders of Series B Preferred Stock under the Nevada Revised Statues, each holder will be entitled to the whole number of votes equal to the number of shares of common stock into which such holder’s Series B Preferred Stock would be convertible on the record date for the vote or consent of stockholders and shall otherwise have voting rights and powers equal to the voting rights and powers of the common stock. Once issued, the shares of Series B Preferred Stock are transferrable by the holder in the holder’s sole option without the consent of the Company, subject to compliance with Section 5 of the Securities Act. The Series B Preferred Stock will rank senior to all other classes of the Company’s capital stock and has a stated value of $1.30 per share (the “Stated Value”). Subject only to the liquidation rights of the holders of Series B Preferred Stock that is then currently issued and outstanding, upon the liquidation, dissolution or winding up of the business of the Company, whether voluntary or involuntary, the Series B Preferred Stock is entitled to receive an amount per share equal to the Stated Value and then receive a pro-rata portion of the remaining assets available for distribution to the holders of common stock on an as-converted to common stock basis. From and after the Closing date, cumulative dividends on each share of Series B Preferred Stock will accrue, on a quarterly basis in arrears, at the rate of 10% per annum on the Stated Value, plus all dividends, whether declared or not, on such share of Series B Preferred Stock (the “Additional Amount”) thereon. All accrued dividends on each share of Series B Preferred Stock are to be paid upon conversion of the Series B Preferred Stock for which the applicable dividend is due. At the option of the Company dividends may be paid in cash or shares of common stock. Each holder of Series B Preferred Stock will also be entitled to receive dividends or distributions on each share of Series B Preferred Stock on an “as converted” into common stock basis when and if dividends are declared on the common stock by the Company’s Board of Directors. Dividends may be paid in cash or property, as determined by the Board of Directors. Subject to the beneficial ownership limitations described below, at any time after the Closing date, each share of Series B Preferred Stock will be convertible at the holder’s option into validly issued, fully paid and non-assessable shares of common stock at a conversion rate (the “Conversion Rate”) determined by dividing the Conversion Amount of such share of Series B Preferred Stock by the conversion price, which is (i) $1.30 or (ii) 75% of the price paid per share by investors in any subsequent offering of the Company’s common stock or common stock equivalents, subject to adjustment as provided herein, subject to adjustment as set forth below (the “Conversion Price”). The Conversion Amount is defined as the Stated Value plus the Additional Amount and any accrued and unpaid late charges with respect to such Stated Value and Additional Amount as of such date of determination. In addition, the shares of Series B Preferred Stock will be convertible at the holder’s option at the Conversion Price any time during the period commencing on the date of the occurrence of a Triggering Event (as defined in the Series B Preferred Designations). A holder of Series B Preferred Stock will not be able to convert the shares into shares of common stock to the extent such conversion or exercise would cause the holder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed 4.99% of the Company’s then outstanding shares of our common stock following such exercise or conversion, subject to a waiver by the holder upon 61 days’ prior notice to the Company. The Conversion Price and the number of shares of common stock issuable upon conversion of the Series B Preferred Stock will be subject to pro-rata adjustment for stock splits, dividends and similar corporate events. In addition, if on or after April 9, 2021, the execution date of the Exchange Agreement, the Company issues or sells, or is deemed to have issued or sold, any shares of common stock, excluding certain specified excluded securities for a consideration per share (the “New Issuance Price”) less than a price equal to the Conversion Price in effect immediately prior to such issue or sale or deemed issuance or sale, then, immediately after such dilutive issuance, the Conversion Price then in effect shall be reduced to the New Issuance Price. The Series B Preferred Designations or any provision hereof (other than the beneficial ownership limitation set forth above) may be modified or amended or the provisions hereof waived with the written consent of the Company and either (i) the holders of a majority of the Series B Preferred Stock then currently outstanding, which must include Cavalry as long as Cavalry (or any of its affiliates) owns at least 5% of the Series B Preferred Stock issued pursuant to the Exchange Agreement, or (ii) Cavalry as long as Cavalry (or any of its affiliates) owns at least 5% of the Series B Preferred Stock issued pursuant to the Exchange Agreement. On the date of the exchange, the Company exchanged 2,694,514 shares of the Company’s Series B Preferred Stock for the principal and interest on four convertible notes payable for $1,477,437, dividends payable on the Series A preferred stock of $105,432 and the Series A preferred stock for $1,006,000 for an aggregate of $2,588,869. On May 17, 2019, Calvary acquired 2,107,356 shares of Series A Preferred Stock and 2,107,356 shares of preferred stock warrants from Pinz Capital Special Opportunities Fund LP.	NOTE 3 – EXCHANGE AGREEMENT On April 9, 2021 Company entered into an Exchange Agreement with Calvary Fund Management, LLC (“Calvary”) pursuant to which it agreed to issue Calvary 2,694,514 shares of its newly designated Series B Convertible Preferred Stock (the “Series B Preferred”) in exchange (the “Exchange”) for (i) 8,480,000 shares of its Series A Convertible Preferred Stock (the “Series A Preferred”), (ii) outstanding common stock purchase warrants (the “Warrants”), and (iii) all principal and accrued interest due under outstanding convertible promissory notes (the “Convertible Notes”, and together with the Series A Preferred and the Warrants, the “Calvary Securities”). The closing of the Exchange (the “Closing”) will occur following the satisfaction or waiver of the conditions set forth in the Exchange Agreement. On the Closing date, subject to the terms and conditions of the Exchange Agreement, the Company will issue the Series B Preferred to Calvary in exchange for the Calvary Securities (which will be cancelled and retired) in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on exemptions provided pursuant to Section 3(a)(9) of the Securities Act. The Series B Preferred Designations designated 2,694,514 shares of the Company’s blank check preferred stock as Series B Preferred Stock. In addition to rights granted to holders of Series B Preferred Stock under the Nevada Revised Statues, each holder will be entitled to the whole number of votes equal to the number of shares of common stock into which such holder’s Series B Preferred Stock would be convertible on the record date for the vote or consent of stockholders, and shall otherwise have voting rights and powers equal to the voting rights and powers of the common stock. Once issued, the shares of Series B Preferred Stock are transferrable by the holder in the holder’s sole option without the consent of the Company, subject to compliance with Section 5 of the Securities Act. The Series B Preferred Stock will rank senior to all other classes of the Company’s capital stock and has a stated value of $1.30 per share (the “Stated Value”). Subject only to the liquidation rights of the holders of Series B Preferred Stock that is then currently issued and outstanding, upon the liquidation, dissolution or winding up of the business of the Company, whether voluntary or involuntary, the Series B Preferred Stock is entitled to receive an amount per share equal to the Stated Value and then receive a pro-rata portion of the remaining assets available for distribution to the holders of common stock on an as-converted to common stock basis. From and after the Closing date, cumulative dividends on each share of Series B Preferred Stock will accrue, on a quarterly basis in arrears, at the rate of 10% per annum on the Stated Value, plus all dividends, whether declared or not, on such share of Series B Preferred Stock (the “Additional Amount”) thereon. All accrued dividends on each share of Series B Preferred Stock are to be paid upon conversion of the Series B Preferred Stock for which the applicable dividend is due. At the option of the Company dividends may be paid in cash or shares of common stock. Each holder of Series B Preferred Stock will also be entitled to receive dividends or distributions on each share of Series B Preferred Stock on an “as converted” into common stock basis when and if dividends are declared on the common stock by the Company’s Board of Directors. Dividends may be paid in cash or property, as determined by the Board of Directors. Subject to the beneficial ownership limitations described below, at any time after the Closing date, each share of Series B Preferred Stock will be convertible at the holder’s option into validly issued, fully paid and non-assessable shares of common stock at a conversion rate (the “Conversion Rate”) determined by dividing the Conversion Amount of such share of Series B Preferred Stock by the conversion price, which is (i) $1.30 or (ii) 75% of the price paid per share by investors in any subsequent offering of the Company’s common stock or common stock equivalents, subject to adjustment as provided herein, subject to adjustment as set forth below (the “Conversion Price”). The Conversion Amount is defined as the Stated Value plus the Additional Amount and any accrued and unpaid late charges with respect to such Stated Value and Additional Amount as of such date of determination. In addition, the shares of Series B Preferred Stock will be convertible at the holder’s option at the Conversion Price any time during the period commencing on the date of the occurrence of a Triggering Event (as defined in the Series B Preferred Designations). A holder of Series B Preferred Stock will not be able to convert the shares into shares of common stock to the extent such conversion or exercise would cause the holder, together with its affiliates, to beneficially own a number of shares of common stock which would exceed 4.99% of the Company’s then outstanding shares of our common stock following such exercise or conversion, subject to a waiver by the holder upon 61 days’ prior notice to the Company. The Conversion Price and the number of shares of common stock issuable upon conversion of the Series B Preferred Stock will be subject to pro-rata adjustment for stock splits, dividends and similar corporate events. In addition, if on or after April 9, 2021, the execution date of the Exchange Agreement, the Company issues or sells, or is deemed to have issued or sold, any shares of common stock, excluding certain specified excluded securities for a consideration per share (the “New Issuance Price”) less than a price equal to the Conversion Price in effect immediately prior to such issue or sale or deemed issuance or sale, then, immediately after such dilutive issuance, the Conversion Price then in effect shall be reduced to the New Issuance Price. The Series B Preferred Designations or any provision hereof (other than the beneficial ownership limitation set forth above) may be modified or amended or the provisions hereof waived with the written consent of the Company and either (i) the holders of a majority of the Series B Preferred Stock then currently outstanding, which must include Cavalry as long as Cavalry (or any of its affiliates) owns at least 5% of the Series B Preferred Stock issued pursuant to the Exchange Agreement, or (ii) Cavalry as long as Cavalry (or any of its affiliates) owns at least 5% of the Series B Preferred Stock issued pursuant to the Exchange Agreement. On the date of the exchange, the Company exchanged 2,694,514 shares of the Company’s Series B Preferred Stock for the principal and interest on four convertible notes payable for $1,477,437, dividends payable on the Series A preferred stock of $105,432 and the Series A preferred stock for $1,006,000 for an aggregate of $2,588,869. On May 17, 2019, Calvary acquired 2,107,356 shares of Series A Preferred Stock and 2,107,356 shares of preferred stock warrants from Pinz Capital Special Opportunities Fund LP.

GOING CONCERN

GOING CONCERN	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
GOING CONCERN
NOTE 4 - GOING CONCERN	NOTE 5 - GOING CONCERN The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had limited revenue and a net operating loss of $361,072 for the three months ended November 30, 2021. The Company has working capital deficit of $26,376,259 and an accumulated deficit of $3,350,368 as of November 30, 2021. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The ability of the Company to fully commence its operations is dependent upon, among other things, obtaining additional financing to continue operations, and execution of its business plan. In response to these concerns, management plans to fund operations through additional debt and equity financing. Debt instruments may be convertible or non-convertible and will vary based on the Company’s needs and financing options available at such times. There can be no assurance that management’s plan will be successful.	NOTE 4 – GOING CONCERN The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company had limited revenue and a net operating loss of $238,991 for the year ended August 31, 2021. The Company has working capital deficit of $238,249 and an accumulated deficit of $2,973,628 as of August 31, 2021. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The ability of the Company to fully commence its operations is dependent upon, among other things, obtaining additional financing to continue operations, and execution of its business plan. In response to these concerns, management plans to fund operations through additional debt and equity financing. Debt instruments may be convertible or non-convertible and will vary based on the Company’s needs and financing options available at such times. There can be no assurance that management’s plan will be successful.

NOTES RECEIVABLE

NOTES RECEIVABLE	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
NOTES RECEIVABLE
NOTE 5 - NOTES RECEIVABLE	NOTE 6 - NOTES RECEIVABLE On April 27, 2020, the Company entered into a Participation Agreement, effective April 27, 2020, with Libertas Funding, LLC, a Connecticut Limited Liability Company (“Libertas”), pursuant to which Libertas offered and the Company accepted to participate with Future Receivables in Purchase Agreement(s) with qualifying merchants, specifically QSI Holding Company, a Delaware Corporation (“QSI”). The Company’s participation buy-in amount was $200,000 with a participation purchase of $264,000 that is estimated to result in weekly payments to the Company for a minimum period of nine months or until the full participation purchase amount has been paid. The $200,000 buy-in was recorded as a Note receivable on the accompanying consolidated balance sheets. On September 1, 2020, Libertas renegotiated this agreement, and the Company will receive weekly payments for $4,921 and extended the term to 38 weeks. The previous weekly payment was $6,984. The final payments was received in April 2021, to fully satisfy the notes receivable. In addition, on April 27, 2020, under the Libertas Participation Agreement, the Company received 45,053 Warrants of QSI Holding Company, a private company, (“QSI Warrants”) to purchase common stock priced at $3.111 per share for common stock par value $0.00001 expiring the 7th anniversary after the issue date. Upon issuance, the Company valued the warrants using the Black Scholes model yielding a total value of $58,443. The Company used the following assumptions upon measurement: QSI Holding Company value per common share of $3.4520, a life of 7 years, an exercise price of $3.111, a risk-free rate of 0.56% and volatility of 32%. In addition, the Company recorded a discount of $58,443 and will record income over the 7-year life of the warrants. On November 8, 2021, the Company entered into a Warrant Assignment Agreement to assign the QSI Warrants issued on April 29, 2020 from QSI Holding Company, Inc. (“QSI”), to Calvary Fund 1 LP (“Calvary”). In consideration of the assignment of the Warrant, Calvary forgives the Company from the principal and interest owing under the Calvary $150,000 promissory note dated August 30, 2021. The warrants are recorded as an equity investment in the accompanying consolidated balance sheets for $-0- and $11,132 at November 30, 2021 and August 31, 2021, respectively. The Company recorded other income of $1,583 and $2,087, respectively for the three months ended November 30, 2021 and 2020, respectively, in the accompanying statement of operations. On September 10, 2021, the Company entered into a convertible promissory notes receivable with ST BioSciences, Ltd., (“STB”). The Company acquired certain assets of STB on November 9, 2021. See Note 3 - Asset Acquis i tion	NOTE 5 – NOTES RECEIVABLE On January 24, 2020, the Company received a promissory note from a supplier, Notis Global, Inc. (“NGBL”). The $112,500 note was issued with an original issue discount of $12,500 or 12.5%. NGBL will repay the promissory note with 12.5% of its sales of derivative products of hemp planted and harvested in 2020. In addition, once the promissory note has been repaid, the Company shall be paid an aggregate of 3.75% of the 2020 derivative products revenues sold by the supplier. The original issue discount is amortized through the term of the note. At August 31, 2020, the Company evaluated the promissory noted under ASU 2016-16, “ Financial Instruments – Credit Losses, (Topic 326)” On April 27, 2020, the Company entered into a Participation Agreement, effective April 27, 2020, with Libertas Funding, LLC, a Connecticut Limited Liability Company (“Libertas”), pursuant to which Libertas offered and the Company accepted to participate with Future Receivables in Purchase Agreement(s) with qualifying merchants, specifically QSI Holding Company, a Delaware Corporation (“QSI”). The Company’s participation buy-in amount was $200,000 with a participation purchase of $264,000 that is estimated to result in weekly payments to the Company for a minimum period of nine months or until the full participation purchase amount has been paid. The $200,000 buy-in was recorded as a Note receivable on the accompanying consolidated balance sheets. On September 1, 2020, Libertas renegotiated this agreement and the Company will receive weekly payments for $4,921 and extended the term to 38 weeks. The previous weekly payment was $6,984. The unpaid balance was $-0- and $132,852 at August 31, 2021 and 2020, respectively. In addition, on April 29, 2020, under the Libertas Participation Agreement, the Company received 45,053 Warrants of QSI Holding Company, a private company, (“QSI Warrants”) to purchase common stock priced at $3.111 per share for common stock par value $0.00001 expiring the 7th anniversary after the issue date. Upon issuance, the Company valued the warrants using the Black Scholes model yielding a total value of $58,443. The Company used the following assumptions upon measurement: QSI Holding Company value per common share of $3.4520, a life of 7 years, an exercise price of $3.111, a risk-free rate of 0.56% and volatility of 32%. In addition, the Company recorded a discount of $58,443 and will record income over the 7-year life of the warrants. The warrants are recorded as an equity investment in the accompanying consolidated balance sheets for $11,132 and $2,783 at August 31, 2021 and 2020, respectively. The Company recorded other income of $8,349 and $2,783, respectively for the years ended August 31, 2021 and 2020, respectively, in the accompanying statement of operations.

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
NOTES PAYABLE
NOTE 6 - NOTES PAYABLE	NOTE 7 - NOTES PAYABLE Short-Term Notes Payable On September 14, 2017, the Company issued a $10,000 promissory note to a limited liability company. The loan bears interest at 5% and has a maturity date of September 15, 2018. The unpaid balance including accrued interest was $12,107 and $11,982 at November 30, 2021 and 2020, respectively. The Company is in default with the repayment terms of the note. On August 30, 2021, the Company issued a $150,000 promissory note to an investor. The loan bears interest at 18% and has a maturity date of August 30, 2022. As discussed in Note 6 - Notes Receivable, Convertible Notes Payable As discussed on Note 4 - Exchange Agreement On August 27, 2019, the Company signed a convertible promissory note with an investor. The $30,000 note was issued with an original issue discount of $3,000 and bears interest at 10% per year. The note principal and interest are convertible into shares of common stock at a 25% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on February 27, 2020. The note has a prepayment penalty of 110% of the principal and interest outstanding if repaid before 180 days from issuance. After February 27, 2020, the payment premium increases to 125% of the principal and interest outstanding and if in default, the payment premium increases to 140% of the principal and interest outstanding. The original issue discount is amortized through the term of the note. On November 25, 2019, the Company signed a convertible promissory note with an investor. The $140,000 note was issued with an original issue discount of $14,000 and bears interest at 10% per year. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on May 25, 2020. The note has a prepayment penalty of 110% of the principal and interest outstanding if repaid before 180 days from issuance. If in default, the payment premium increases to 140% of the principal and interest outstanding. The original issue discount is amortized through the term of the note. On January 27, 2020, the Company signed a convertible promissory note with an investor. The $555,000 note was issued with an original issue discount of $55,500 and bears interest at 10% per year. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on July 27, 2020. The note has a prepayment penalty of 115% of the principal and interest outstanding if repaid more than 30 days after note issuance. If in default, the payment premium increases to 140% of the principal and interest outstanding. The original issue discount is amortized through the term of the note. On April 27, 2020, the Company signed a convertible promissory note with an investor. The $259,615 note was issued with an original issue discount of $57,115 and bears interest at -0-% per year. The Company recorded the self-amortizing convertible promissory note using the effective interest rate method to calculate the loan payable at $202,500 and accrued interest at $57,115. The note requires nine equal payments due starting June 15, 2020 for $28,846. In the event the Company fails to make the $28,846 installment payment by the 15th day of each designated month and/or fails to cure any missed installment payment within five (5) calendars days following the due date, or the Company defaults, the defaulted amount owed shall be 130% of the total outstanding balance owed by the Company. The default interest rate for missing an installment payment shall be 18% and the conversion into common stock shall be at a price of $0.02 per common stock. The note principal and interest are convertible into shares of common stock at the lower of $0.02 per share or a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on February 21, 2021. The Company made the first payment on June 15, 2020 for $28,846 and a partial payment of $10,000 on July 15, 2020. The original issue discount is amortized through the term of the note. The conversion features meet the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). See Note 11 - Derivative Liability At November 30, 2021 and August 31, 2021, the outstanding principal balances of the convertible notes payable was $-0-. The Company recorded interest accretion on the debt discount of $-0- and $80,511 for the three months ended November 30, 2021 and 2020, respectively, and interest expense of $5,139 and $36,750 for the three months ended November 30, 2021 and 2020, respectively, in the accompanying consolidated statements of operations.	NOTE 6 – NOTES PAYABLE Short-Term Notes Payable On September 14, 2017, the Company issued a $10,000 promissory note to a limited liability company. The loan bears interest at 5% and has a maturity date of September 15, 2018. The unpaid balance including accrued interest was $11,982 and $11,482 at August 31, 2021 and 2020, respectively. The Company is in default with the repayment terms of the note. On May 31, 2018, the Company issued a $39,500 promissory note to a company. The loan bears interest at 0% and has a maturity date of November 30, 2018. During March 2020, it was discovered the promissory note was fully paid-off on August 6, 2018 and inadvertently recorded as an operating expense for the year ended August 31, 2018. At May 31, 2020, the Company wrote-off the promissory note to operating expense. The unpaid balance was $-0- at August 31, 2021 and 2020. On August 30, 2021, the Company issued a $150,000 promissory note to an investor. The loan bears interest at 18% and has a maturity date of August 30, 2022. The unpaid balance including accrued interest was $150,074 August 31, 2021. Convertible Notes Payable As discussed on Note 3 – Exchange Agreement On August 27, 2019, the Company signed a convertible promissory note with an investor. The $30,000 note was issued with an original issue discount of $3,000 and bears interest at 10% per year. The note principal and interest are convertible into shares of common stock at a 25% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on February 27, 2020. The note has a prepayment penalty of 110% of the principal and interest outstanding if repaid before 180 days from issuance. After February 27, 2020, the payment premium increases to 125% of the principal and interest outstanding and if in default, the payment premium increases to 140% of the principal and interest outstanding. The original issue discount is amortized through the term of the note. The unpaid balance including accrued interest was $-0- and $46,870 at August 31, 2021 and 2020, respectively. On November 25, 2019, the Company signed a convertible promissory note with an investor. The $140,000 note was issued with an original issue discount of $14,000 and bears interest at 10% per year. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on May 25, 2020. The note has a prepayment penalty of 110% of the principal and interest outstanding if repaid before 180 days from issuance. If in default, the payment premium increases to 140% of the principal and interest outstanding. The original issue discount is amortized through the term of the note. The unpaid balance including accrued interest was $-0- and $212,577 at August 31, 2021 and 2020, respectively. On January 27, 2020, the Company signed a convertible promissory note with an investor. The $555,000 note was issued with an original issue discount of $55,500 and bears interest at 10% per year. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The note matured on July 27, 2020. The note has a prepayment penalty of 115% of the principal and interest outstanding if repaid more than 30 days after note issuance. If in default, the payment premium increases to 140% of the principal and interest outstanding. The original issue discount is amortized through the term of the note. The unpaid balance including accrued interest was $-0- and $825,475 at August 31, 2021 and 2020, respectively. On April 27, 2020, the Company signed a convertible promissory note with an investor. The $259,615 note was issued with an original issue discount of $57,115 and bears interest at -0-% per year. The Company recorded the self-amortizing convertible promissory note using the effective interest rate method to calculate the loan payable at $202,500 and accrued interest at $57,115. The note requires nine equal payments due starting June 15, 2020 for $28,846. In the event the Company fails to make the $28,846 installment payment by the 15 th The conversion features meet the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). See Note 10 - Derivative Liability At August 31, 2021 and 2020, the outstanding principal balances of the convertible notes payable, net of debt discount was $-0- and $831,170, respectively. The Company recorded interest accretion on the debt discount of $114,599 and $869,967 for the years ended August 31, 2021 and 2020, respectively, in the accompanying consolidated statements of operations.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
RELATED PARTY TRANSACTIONS
NOTE 7 - RELATED PARTY TRANSACTIONS	NOTE 8 - RELATED PARTY TRANSACTIONS As of November 30, 2021, and August 31, 2021, the Company owed $-0- and $64,600, respectively to our former President and Director. The balance due is recorded as related party payable in the accompanying consolidated balance sheets.	NOTE 7 – RELATED PARTY TRANSACTIONS As of August 31, 2021, and 2020, the Company owed $64,600 and $73,469, respectively to its President and Director. The balance due is recorded as related party payable in the accompanying consolidated balance sheets.

STOCKHOLDERS EQUITY

STOCKHOLDERS EQUITY	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
STOCKHOLDERS EQUITY
NOTE 8 - STOCKHOLDERS EQUITY	NOTE 9 - STOCKHOLDERS’ EQUITY Preferred Stock There were -0- of Series A Convertible Preferred Stock issued and outstanding as of November 30, 2021 and August 31, 2021. As discussed on Note 4 - Exchange Agreement On September 7, 2021, the Company consummated the initial tranche of its $2 million financing contemplated by that certain Series B-1 Purchase Agreement between the Company and an investor pursuant to which the Company agreed to issue and sell the investor up to 2,694,514 shares of its newly designated Series B-1 Convertible Preferred Stock (the “Series B-1 Preferred”) at a Stated Value per share price of $0.742245 (or $2,000,000 in the aggregate). At the initial closing, the Company issued 673,628 shares of Series B-1 Preferred to the investor and received $500,000 in gross proceeds. On October 28, 2021, the Company consummated the second tranche of the Series B-1 Preferred Stock investment, issuing an additional 673,628 shares of its Series B-1 Preferred Stock to the investor at a price per share of $0.742245 or $500,000.00 in the aggregate. On November 9, 2021, the Company consummated the third and final tranche of the Series B-1 Preferred Stock investment, issuing an additional 1,347,256 shares of its Series B-1 Preferred Stock to the investor a price per share of $0.742245 or $1,000,000.00 in the aggregate. The aggregate gross proceeds of $2,000,000 was used by the Company as working capital. On November 24, 2021, the Company entered into, and consummated the financing contemplated by, that certain Series B-1 Purchase Agreement between the Company and an investor, pursuant to which the Company issued and sold to the investor 2,694,514 shares of its Series B-1 Preferred at a per share price of $0.742245, or $2,000,000. The aggregate gross proceeds of $2,000,000 was used by the Company as working capital. There were 8,083,542 and 2,694,514 shares of Series B and Series B-1 Convertible Preferred Stock issued and outstanding as of November 30, 2021 and August 31, 2021, respectively. Common Stock On January 8, 2021, a 308-to-1 reverse stock split was declared effective. In accordance with the terms of all such instruments, the conversion ratio of the Company’s outstanding Series A Convertible Preferred Stock and its various convertible promissory notes, together with the exercise price of its outstanding warrants, were proportionally adjusted to give effect to the reverse stock split. The Company is authorized to issue up to 200,000,000 shares of $0.001 par value common stock. As discussed in Note 3 - Asset Acquisition, There were 20,020,239 and 188,616 common shares issued and outstanding as of November 30, 2021 and August 31, 2021, respectively.	NOTE 8 – STOCKHOLDERS’ EQUITY Preferred Stock There were -0- and 8,480,000 shares of Series A Convertible Preferred Stock issued and outstanding as of August 31, 2021 and 2020, respectively. As discussed on Note 3 – Exchange Agreement Common Stock On January 8, 2021, a 308-to-1 reverse stock split was declared effective. In accordance with the terms of all such instruments, the conversion ratio of the Company’s outstanding Series A Convertible Preferred Stock and its various convertible promissory notes, together with the exercise price of its outstanding warrants, were proportionally adjusted to give effect to the reverse stock split. The Company is authorized to issue up to 200,000,000 shares of $0.001 par value common stock. On, January 28, 2020, the Company entered into an agreement to repurchase 252,833 restricted shares of the Company’s common stock from an investor. The Company paid $80,000 or $0.3164 per share and immediately retired the shares. There were 188,616 and 187,194 common shares issued and outstanding as of August 31, 2021 and 2020, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
COMMITMENTS AND CONTINGENCIES
NOTE 9 - COMMITMENTS AND CONTINGENCIES	NOTE 10 - COMMITMENTS AND CONTINGENCIES The Company could become a party to various legal actions arising in the ordinary course of business. Matters that are probable of unfavorable outcomes to the Company and which can be reasonably estimated are accrued. Such accruals are based on information known about the matters, the Company’s estimates of the outcomes of such matters and its experience in contesting, litigating and settling similar matters. As of the date of this report, there are no pending legal proceedings to which the Company is a party or of which any of their property is the subject, nor are there any such proceedings known to be contemplated by governmental authorities. In December 2019, a novel strain of COVID-19 was reported in China. Since then, the COVID-19 has spread globally including across North America and the United States. The spread of COVID-19 from China to other countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of a new disease, on March 11, 2020. Specifically, we caution that our business could be materially and adversely affected by the risks, or the public perception of the risks, related to the outbreak of COVID-19. To date, COVID has directly impacted the ability we have to participate in trade show events and other in-person marketing. The risk of a pandemic, or public perception of the risk, could cause customers to avoid public places, including retail properties, and could cause temporary or long-term disruptions in our supply chains and/or delays in the delivery of our inventory to customers. Further, such risks could also adversely affect retail customers’ financial condition, resulting in reduced spending on premium products.	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company could become a party to various legal actions arising in the ordinary course of business. Matters that are probable of unfavorable outcomes to the Company and which can be reasonably estimated are accrued. Such accruals are based on information known about the matters, the Company’s estimates of the outcomes of such matters and its experience in contesting, litigating and settling similar matters. As of the date of this report, there are no pending legal proceedings to which the Company is a party or of which any of their property is the subject, nor are there any such proceedings known to be contemplated by governmental authorities.

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
DERIVATIVE LIABILITY
NOTE 10 - DERIVATIVE LIABILITY	NOTE 11 - DERIVATIVE LIABILITY As discussed on Note 4 - Exchange Agreement Preferred Stock Warrants During the year ended August 31, 2018, the Company issued a total of 27,532 warrants to purchase common stock as part of its preferred stock offering. The warrants are exercisable for a period of three years at $50.82 per share. Additionally, the warrant holder is entitled to a cashless exercise after nine months from issuance in which the holder is entitled to receive a number of shares equal to: [A] the number of outstanding warrant shares under the original issuance multiplied by [B] the greater of the trailing five day volume weighted average price less [A] the number of outstanding warrant shares under the original issuance multiplied by [C] the exercise price of the warrant under the original issuance divided by [D] the lesser of the arithmetic average of the volume weighted average price during the five trailing trading days or the volume weighted average price for the trading day immediately prior to the cashless exercise election. For clarity, the resulting formula is [(A x B) - (A x C)] / D. The Company analyzed the conversion features of the cashless exercise feature in the warrants issued for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded features should be classified as a derivative liability because the exercise price of these warrants are subject to a variable rate. The Company has determined that warrants are not considered to be solely indexed to the Company’s own stock and is therefore not afforded equity treatment. In accordance with ASC 815, the Company has recorded a derivative liability. Upon issuance, the Company valued the derivative using a Black-Scholes model yielding a total value of $674,012 which was expensed during the year ended August 31, 2018. The Company used the following assumptions upon initial measurement: value per common share of $27.72, a remaining life of 3.0 years, an exercise price of $50.82, a risk-free rate of 2.77% and volatility of 195%. As discussed on Note 4 - Exchange Agreement Convertible Notes Payable As discussed in Note 7 - Notes Payable On August 27, 2019, the Company signed a $30,000 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at a 25% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determined it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $50,277 which was recorded as a derivative liability during the year ended August 31, 2019. The Company used the following assumptions upon initial measurement: value per common share of $2.74, a remaining life of 6 months, an exercise price of $1.30, a risk-free rate of 1.98% and volatility of 287%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $3,000 and a derivative discount of $27,000 which aggregated a total discount of $30,000 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $23,277 was recorded in the accompanying statement of operations. On November 25, 2019, the Company signed a $140,000 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determined it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $172,608 which was recorded as a derivative liability during the three months ended November 30, 2019. The Company used the following assumptions upon initial measurement: value per common share of $1.54, a remaining life of 6 months, an exercise price of $0.93, a risk-free rate of 1.61% and volatility of 275%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $14,000 and a derivative discount of $126,000 which aggregated a total discount of $140,000 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $46,608 was recorded in the accompanying statement of operations. On January 27, 2020, the Company signed a $555,000 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determined it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $929,300 which was recorded as a derivative liability during the three months ended February 29, 2020. The Company used the following assumptions upon initial measurement: value per common share of $6.65, a remaining life of 6 months, an exercise price of $3.13, a risk-free rate of 1.57% and volatility of 281%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $55,500 and a derivative discount of $499,500 which aggregated a total discount of $555,000 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $429,800 was recorded in the accompanying statement of operations. On April 27, 2020, the Company signed a $259,615 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at $0.02 per share or a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determined it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $587,772 which was recorded as a derivative liability during the three months ended May 31, 2020. The Company used the following assumptions upon initial measurement: value per common share of $3.17, a remaining life of 9 months, an exercise price of $1.28, a risk-free rate of 0.17% and volatility of 304%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $57,115 and a derivative discount of $202,500 which aggregated a total discount of $259,615 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $385,272 was recorded in the accompanying statement of operations. Derivative Liability Summary As of November 30, 2021 and August 31, 2021, the Company had no derivative liability in the accompanying consolidated balance sheet, and (gain) loss on change in fair value of the derivative liability of $-0- and $92,642 for the three months ended November 30, 2021 and 2020, respectively, in the accompanying consolidated statement of operations. In addition, the Company amortized $-0- and $80,512 to interest accretion during the three months ended November 30, 2021 and 2020, respectively, in the accompanying consolidated statement of operations for the preferred stock warrants and derivative convertible notes payable.	NOTE 10 – DERIVATIVE LIABILITY As discussed on Note 3 – Exchange Agreement Preferred Stock Warrants During the year ended August 31, 2018, the Company issued a total of 27,532 warrants to purchase common stock as part of its preferred stock offering. The warrants are exercisable for a period of three years at $50.82 per share. Additionally, the warrant holder is entitled to a cashless exercise after nine months from issuance in which the holder is entitled to receive a number of shares equal to: [A] the number of outstanding warrant shares under the original issuance multiplied by [B] the greater of the trailing five day volume weighted average price less [A] the number of outstanding warrant shares under the original issuance multiplied by [C] the exercise price of the warrant under the original issuance divided by [D] the lesser of the arithmetic average of the volume weighted average price during the five trailing trading days or the volume weighted average price for the trading day immediately prior to the cashless exercise election. For clarity, the resulting formula is [(A x B) – (A x C)] / D. The Company analyzed the conversion features of the cashless exercise feature in the warrants issued for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded features should be classified as a derivative liability because the exercise price of these warrants are subject to a variable rate. The Company has determined that warrants are not considered to be solely indexed to the Company’s own stock and is therefore not afforded equity treatment. In accordance with ASC 815, the Company has recorded a derivative liability. Upon issuance, the Company valued the derivative using a Black-Scholes model yielding a total value of $674,012 which was expensed during the year ended August 31, 2018. The Company used the following assumptions upon initial measurement: value per common share of $27.72, a remaining life of 3.0 years, an exercise price of $50.82, a risk-free rate of 2.77% and volatility of 195%. As discussed on Note 3 – Exchange Agreement The following table summarizes all stock warrant activity for the years ended August 31, 2021: Warrants Weighted- Average Exercise Price Per Share Outstanding, August 31, 2020 27,532 $ 50.82 Granted - - Exercised - - Forfeited - - Cancelled (27,532 ) (50.82 ) Outstanding, August 31, 2021 - $ - Convertible Notes Payable As discussed in Note 6 – Notes Payable On August 27, 2019, the Company signed a $30,000 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at a 25% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determine it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $50,277 which was recorded as a derivative liability during the year ended August 31, 2019. The Company used the following assumptions upon initial measurement: value per common share of $2.74, a remaining life of 6 months, an exercise price of $1.30, a risk-free rate of 1.98% and volatility of 287%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $3,000 and a derivative discount of $27,000 which aggregated a total discount of $30,000 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $23,277 was recorded in the accompanying statement of operations. On November 25, 2019, the Company signed a $140,000 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determine it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $172,608 which was recorded as a derivative liability during the three months ended November 30, 2019. The Company used the following assumptions upon initial measurement: value per common share of $1.54, a remaining life of 6 months, an exercise price of $0.93, a risk-free rate of 1.61% and volatility of 275%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $14,000 and a derivative discount of $126,000 which aggregated a total discount of $140,000 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $46,608 was recorded in the accompanying statement of operations. On January 27, 2020, the Company signed a $555,000 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determine it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $929,300 which was recorded as a derivative liability during the three months ended February 29, 2020. The Company used the following assumptions upon initial measurement: value per common share of $6.65, a remaining life of 6 months, an exercise price of $3.13, a risk-free rate of 1.57% and volatility of 281%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $55,500 and a derivative discount of $499,500 which aggregated a total discount of $555,000 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $429,800 was recorded in the accompanying statement of operations. On April 27, 2020, the Company signed a $259,615 convertible promissory note with an investor. The note principal and interest are convertible into shares of common stock at $0.02 per share or a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company. The Company analyzed the conversion feature and determine it meets the definition of a derivative liability instrument because the conversion rate is variable and therefore does not meet the “fixed-for-fixed” criteria outlined in ASC 815-40-15. As a result, the conversion features of the notes are recorded as a derivative liability at fair value and marked-to-market each period with the changes in fair value each period charged or credited to other income (expense). Upon issuance, the Company valued the derivative using a Monte Carlo simulation model yielding a total value of $587,772 which was recorded as a derivative liability during the three months ended May 31, 2020. The Company used the following assumptions upon initial measurement: value per common share of $3.17, a remaining life of 9 months, an exercise price of $1.28, a risk-free rate of 0.17% and volatility of 304%. In addition, the Company calculated the derivative discount as the difference between the conversion price and the fair market value of the Company’s common stock on the date of issuance. The Company recorded an original issue discount of $57,115 and a derivative discount of $202,500 which aggregated a total discount of $259,615 and was recorded as a discount in the accompanying consolidated balance sheet. On the date of issuance, a net loss of $385,272 was recorded in the accompanying statement of operations. Derivative Liability Summary As of August 31, 2021 and 2020, the Company had derivative liabilities totaling $-0- and $1,454,480, respectively, in the accompanying consolidated balance sheet, and (gain) loss on change in fair value of the derivative liability of ($1,454,480) and ($301,581) for the years ended August 31, 2021 and 2020, respectively, in the accompanying consolidated statement of operations. In addition, the Company amortized $114,599 and $869,967 to interest accretion during the years ended August 31, 2021 and 2020, respectively, in the accompanying consolidated statement of operations for the preferred stock warrants and derivative convertible notes payable.

MATERIAL CONTRACTS

MATERIAL CONTRACTS	12 Months Ended
	Aug. 31, 2021
MATERIAL CONTRACTS
NOTE 11 - MATERIAL CONTRACTS	NOTE 11 – MATERIAL CONTRACTS On September 4, 2019, the Company signed an initial non-binding letter of intent with NanoPeak Performances, LLC with a subsequent addendum for the sale of the majority of its existing inventory as well as the exclusive license to Gridiron intellectual property and other intangible assets. During October 2019, NanoPeak Performances paid a $25,000 non-refundable deposit on the transaction. The Company recorded the deposit in accrued expenses in accompanying consolidated balance sheet. On May 31, 2020, the Company determined the non-binding letter of intent terminated and wrote-off the $25,000 non-refundable deposit other income. In November 2019, the Company made a strategic decision to expand into the cannabinoids (CBD) oil extraction business and on or about November 27, 2019, the Company signed a Supply Agreement with Notis Global, Inc. (“NGBL”), a grower to purchase 10,000 pounds of industrial hemp (biomass) and was processed into crude during the three months ended May 31, 2020. During November 2019, the Company paid $100,000 to the supplier and recorded the purchase in inventory in the accompanying consolidated balance sheet. During January 2020, the Company purchased an additional 30,000 pounds of industrial hemp (biomass) for $5 a pound or $150,000 under the agreement. On August 31, 2020, the Company wrote-down $115,000 of its recently purchased industrial hemp (biomass) raw material to fair market value of $35,000. On May 31, 2021, the Company wrote-down $19,100 of its industrial hemp (biomass) and other raw material to fair market value of $17,000. The write-down was recorded as an impairment charge in the accompanying statements of operations. On December 13, 2019, the Company signed a Toll Processing Agreement with a corporation to process industrial hemp (biomass) into the CBD product. The contract is valued at $100,000. During the year ending August 31, 2020, the Company spent $72,500 to fulfill the contract. On January 24, 2020, the Company signed a Collaboration Agreement with a supplier, Notis Global, Inc. (“NGBL”), to explore and consider potential business opportunities for the parties within various segments of the hemp CBD supply chain including cultivation, extraction and purification and retail products. As consideration for the services to be provided by the Company, NGBL shall issue to the Company 2.5 billion shares of NGBL restricted common stock. Either party may terminate this agreement at any time upon 10 business days’ written notice. The equity investment is valued at $250,000 or 20% ownership of NGBL, however, NGBL is not current with their filing with the Securities and Exchange Commission and do not have the authorized shares to fulfill the agreement. The Company evaluated the shares of NGBL and determined there was $-0- value at August 31, 2021.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Aug. 31, 2021
INCOME TAXES
NOTE 12 - INCOME TAXES	NOTE 12 – INCOME TAXES The Company’s policy is to provide for deferred income taxes based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect when the differences are expected to reverse. The U.S. Tax Cuts and Jobs Act (TCJA) legislation reduces the U.S. federal corporate income tax rate from 35.0% to 21.0% and is effective June 22, 2018 for the Company. We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. When it is more likely than not that a tax asset cannot be realized through future income the Company must allow for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carryforwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carryforward period. The Company is not aware of any uncertain tax position that, if challenged, would have a material effect on the financial statements for the year ended August 31, 2021 or during the prior three years applicable under FASB ASC 740. We did not recognize any adjustment to the liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of accumulated deficit on the consolidated balance sheet. All tax returns for the Company remain open for examination. The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows: 2021 2020 Income tax provision at the federal statutory rate 21 % 21 % Effect on operating losses (21 %) (21 %) The net deferred tax assets consist of the following: August 31, 2021 August 31, 2020 Deferred tax asset $ 615,839 $ 807,225 Valuation allowance (615,839 ) (807,225 ) Net deferred tax asset $ - $ - The change in the valuation allowance for the year ended August 31, 2021 was an increase of $191,836.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
SUBSEQUENT EVENTS
NOTE 13 - SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS On January 1, 2022, Timothy S. Orr resigned as Interim Chief Financial Officer effective as of January 14, 2022. Mr. Orr is resigning to pursue other business opportunities. Mr. Orr will remain a member of the Company’s board of directors. On December 21, 2021, the Board unanimously approved (i) an amendment to the Company’s Certificate of Incorporation to change its corporate name to “Innovation1 Biotech, Inc.” and (ii) to change the ticker symbol of the Company’s common stock to “INVB” or a similar ticker symbol as approved by the Financial Industry Regulatory Authority (“FINRA”). On January 13, 2022, the Company entered into an Amendment No. 1 to Purchase Agreement with Ingenius Biotech S.L. to modify the terms of the Amended and Restated Asset Purchase Agreement dated November 5, 2021 as discussed in Note 3 - Asset Acquisition a) Section 3.2(a) of the Purchase Agreement is hereby deleted in its entirety and replaced with the following: “(b) One hundred fifty thousand U.S. dollars ($150,000) at Closing (the “Closing Consideration”)”. b) Section 3.2(b) of the Purchase Agreement is hereby amended by deleting the phrase “to September 24th, 2021” and replacing it with “by December 31, 2021”. c) Section 3.2(c) of the Purchase Agreement is hereby deleted in its entirety and replaced with the following: “(c) one million five hundred thousand U.S. dollars ($1,500,000) on June 30, 2022.”; and d) Section 3.2(d) of the Purchase Agreement is hereby deleted in its entirety and replaced with the following: “(d) one million five hundred thousand U.S. dollars ($1,500,000) on December 31, 2022. The Company has evaluated all other events occurring subsequently to these financial statements through January 19, 2022 and determined there were no other items to disclose.	NOTE 13 – SUBSEQUENT EVENTS On September 7, 2021, the Company consummated the initial tranche of its $2 million financing contemplated by that certain Series B-1 Purchase Agreement between the Company and Lincoln Park Capital Fund, LLC (“LPC”) pursuant to which the Company agreed to issue and sell to LPC up to 2,694,514 shares of its newly designated Series B-1 Convertible Preferred Stock (the “Series B-1 Preferred”) at a Stated Value per share price of $0.742245 (or $2,000,000 in the aggregate). At the initial closing, the Company issued 673,628 shares of Series B-1 Preferred to LPC and received $500,000 in gross proceeds. On October 28, 2021, the Company consummated the second tranche of the Series B-1 Preferred Stock investment, issuing an additional 637,628 shares of its Series B-1 Preferred Stock to LPC at a price per share of $0.742245 or $500,000.00 in the aggregate. On November 9, 2021, the Company consummated the third and final tranche of the Series B-1 Preferred Stock investment, issuing an additional 1,347,256 shares of its Series B-1 Preferred Stock to LPC at a price per share of $0.742245 or $1,000,000.00 in the aggregate. The aggregate gross proceeds of $2,000,000 will be used by the Company as working capital On November 8, 2021, the Company entered into a Warrant Assignment Agreement to assign the QSI Warrants issued on April 29, 2020 from QSI Holding Company, Inc. (“QSI”), to Calvary Fund 1 LP (“Calvary”). As discussed in Note – 5 Notes Receivable On November 9, 2021, the Company completed its acquisition (the “Acquisition”) of all of the assets, including intellectual property assets, relating to Mioxal®, a nutraceutical complex composed of essential amino acids, natural coenzymes and minerals, held by ST BioSciences, Ltd., a company organized under the laws of England and Wales (“ STB SEC On November 24, 2021, the Company entered into, and consummated the financing contemplated by, that certain Series B-1 Purchase Agreement between the Company and L1 Capital Opportunities Master Fund Ltd. (“L1 Capital”), pursuant to which the Company issued and sold to L1 Capital 2,694,514 shares of its Series B-1 Preferred at a per share price of $0.742245, or $2,000,000 in the aggregate Pursuant to the terms of the respective purchase agreements with LPC and L1 Capital, each of LPC and L1 Capital agreed, for a period of 180 days following the final closing of such transaction, not to offer, sell, contract to sell, pledge, hypothecate, grant any option, right or warrant for the sale of, purchase any option or contract to sell, sell any option or contract to purchase, or otherwise encumber, dispose of or transfer, or grant any rights with respect to, directly or indirectly, any shares of Series B-1 Preferred or any shares of the Company’s common stock issuable upon conversion of the Series B-1 Preferred. In addition, each of LPC and L1 Capital, along with the holders of the Company’s Series B Preferred Stock has been granted the right (until the earlier of (i) the sixteen (16) month anniversary of the Closing Date or (ii) the listing of the Common Stock on a national securities exchange) to participate in up to 10% of the Company’s future equity or equity-linked financings. Furthermore, the Company granted these stockholders certain piggyback registration rights with respect to the Common Stock issuable upon conversion of the Series B-1 Preferred and Series B Preferred issued to such stockholder. The transactions described above are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Company has evaluated all other events occurring subsequently to these financial statements through December 10, 2021 and determined there were no other items to disclose.

RESTATEMENT

RESTATEMENT	3 Months Ended
	Nov. 30, 2021
RESTATEMENT
RESTATEMENT	NOTE 13 - RESTATEMENT The following table summarizes the changes to the Consolidated Statements of Cash Flow (unaudited): For the Three Months Ended Restated Previous November 30, November 30, 2021 2021 Change Cash flows from investing activities: Cash paid for asset purchase (350,000 ) (850,000 ) 500,000 Notes receivable investment (500,000 ) - (500,000 ) Net cash used in investing activities (850,000 ) (850,000 ) -

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation	This summary of accounting policies for Gridiron is presented to assist in understanding the Company’s financial statements. The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting) and have been consistently applied in the preparation of the financial statements.	This summary of accounting policies for Gridiron is presented to assist in understanding the Company’s financial statements. The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting) and have been consistently applied in the preparation of the financial statements.
Reclassifications	Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results.	Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. Estimates are used when accounting for fair value calculations related to embedded conversion features of outstanding convertible notes payable. As discussed on Note 4 - Exchange Agreement	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. Estimates are used when accounting for fair value calculations related to embedded conversion features of outstanding convertible notes payable. As discussed on Note 3 – Exchange Agreement
Cash	For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. The Company had $2,933,712 and $137,476 of cash as of November 30, 2021 and August 31, 2021, respectively. The 2,976,236increase was from our Series B-1 stock subscriptions as discussed in Note 9 - Stockholders’ Equity.	For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. The Company had $137,476 and $17,881 of cash as of August 31, 2021 and 2020, respectively.
Revenue Recognition	Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery.	Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery.
Fair Value of Financial Instruments	Fair value of certain of the Company’s financial instruments including cash, prepaid expenses, accounts payable, accrued expenses, notes payable, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value investments. Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of income. As discussed in Note 11 - Derivative Liability, Note 4 - Exchange Agreement	Fair value of certain of the Company’s financial instruments including cash, prepaid expenses, accounts payable, accrued expenses, notes payable, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value investments. Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of income. As discussed in Note 10 – Derivative Liability, Note 3 – Exchange Agreement
Derivative Liabilities	The Company generally does not use derivative financial instruments to hedge exposures to cash flow or market risks. However, certain other financial instruments, such as warrants and embedded conversion features on the convertible debt, are classified as derivative liabilities due to protection provisions within the agreements. Convertible notes payable are initially recorded at fair value using the Monte Carlo model and subsequently adjusted to fair value at the close of each reporting period. The preferred stock warrants are initially recorded at fair value using the Black Scholes model and subsequently adjusted to fair value at the close of each reporting period. The Company accounts for derivative instruments and debt instruments in accordance with the interpretive guidance of ASC 815, ASU 2017-11, and associated pronouncements related to the classification and measurement of warrants and instruments with conversion features.	The Company generally does not use derivative financial instruments to hedge exposures to cash flow or market risks. However, certain other financial instruments, such as warrants and embedded conversion features on the convertible debt, are classified as derivative liabilities due to protection provisions within the agreements. Convertible notes payable are initially recorded at fair value using the Monte Carlo model and subsequently adjusted to fair value at the close of each reporting period. The preferred stock warrants are initially recorded at fair value using the Black Scholes model and subsequently adjusted to fair value at the close of each reporting period. The Company accounts for derivative instruments and debt instruments in accordance with the interpretive guidance of ASC 815, ASU 2017-11, and associated pronouncements related to the classification and measurement of warrants and instruments with conversion features.
Income Taxes	Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Use of net operating loss carry forwards for income tax purposes may be limited by Internal Revenue Code section 382 if a change of ownership occurs.	Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Use of net operating loss carry forwards for income tax purposes may be limited by Internal Revenue Code section 382 if a change of ownership occurs.
Principals of Consolidation	The consolidated financial statements represent the results of Gridiron BioNutrients, Inc, its wholly owned subsidiary, Gridiron Ventures and the assets, processes, and results therefrom. All intercompany transactions and balances have been eliminated. All financial information has been prepared in conformity with accounting principles generally accepted in the United States of America.	The consolidated financial statements represent the results of Gridiron BioNutrients, Inc, its wholly owned subsidiary, Gridiron Ventures and the assets, processes, and results therefrom. All intercompany transactions and balances have been eliminated. All financial information has been prepared in conformity with accounting principles generally accepted in the United States of America.
Property and Equipment	Property and equipment are carried at cost. Expenditures for maintenance and repairs are expensed in the period incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed for financial statement purposes on a straight-line basis over estimated useful lives of the related assets and the modified accelerated cost recovery system for federal income tax purposes. The estimated useful lives of depreciable assets are: Estimated Useful Lives Computer and other equipment 3 years Vehicle 5 years The Company’s property and equipment consisted of the following as of November 30, 2021 and August 31, 2021: November 30, 2021 August 31, 2021 Computer Equipment $ -0- $ 1,569 Other -0- 3,587 Accumulated depreciation -0- (4,558 ) Net book value $ -0- $ 598 With the asset acquisition as discussed in Note 3 - Asset Acquisition	Property and equipment are carried at cost. Expenditures for maintenance and repairs are expensed in the period incurred. Renewals and betterments that materially extend the life of the assets are capitalized. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. Depreciation is computed for financial statement purposes on a straight-line basis over estimated useful lives of the related assets and the modified accelerated cost recovery system for federal income tax purposes. The estimated useful lives of depreciable assets are: Estimated Useful Lives Computer and other equipment 3 years Vehicle 5 years The Company’s property and equipment consisted of the following as of August 31, 2021 and 2020: August 31, 2021 August 31, 2020 Computer Equipment $ 1,569 $ 1,569 Other 3,587 3,587 Accumulated depreciation (4,558 ) (3,144 ) Net book value $ 598 $ 2,012 Depreciation expense was $1,414 and $2,613 for the years ended August 31, 2021 and 2020, respectively.
Inventories	Inventories consist of raw materials and T-free distillate and are stated at the lower of cost or net realizable value using the first‑in, first‑out method. The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write‑downs for excess, defective and obsolete inventory are recorded as impairment expense in the accompanying statement of operations. The Company wrote-off $17,000and $-0- of obsolete inventory or inventory below market value for the for the three months ended November 30, 2021 and 2020, respectively. A summary of the Company’s inventory as of November 30, 2021 and August 31, 2021 are as follows: Type November 30, 2021 August 31, 2021 Raw Materials $ -0- $ -0- T-free Distillate -0- 17,000 Total Inventory $ -0- $ 17,000	Inventories consist of raw materials and T-free distillate and are stated at the lower of cost or net realizable value using the first‑in, first‑out method. The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write‑downs for excess, defective and obsolete inventory are recorded as impairment expense in the accompanying statement of operations. The Company wrote-off $19,450 and $485,662 of obsolete inventory or inventory below market value for the for the years ended August 31, 2021 and 2020, respectively. A summary of the Company’s inventory as of August 31, 2021 and 2020 are as follows: Type August 31, 2021 August 31, 2020 Raw Materials $ -0- $ 450 T-free Distillate 17,000 37,000 Total Inventory $ 17,000 $ 37,450
Basic Income (Loss) Per Share	Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. The Series B and Series B1 Convertible Preferred shares would convert to 8,083,542 shares of the Company’s common stock in addition to the 20,020,239 outstanding shares at November 30, 2021. The Company calculates diluted earnings per share by dividing the Company’s net income available to common shareholders less preferred dividends by the diluted weighted average number of shares outstanding during the period. The conversion of the Company’s Series B and Series B1 Convertible Preferred shares are excluded from the computation of diluted earnings per share as they are anti-dilutive due to the Company’s operating losses for the three months ended November 30, 2021 and 2020.	Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. The Series B Convertible Preferred shares would convert to 2,694,514 shares of the Company’s common stock in addition to the 188,616 outstanding shares at August 31, 2021. The Company calculates diluted earnings per share by dividing the Company’s net income available to common shareholders less preferred dividends by the diluted weighted average number of shares outstanding during the period. The conversion of the Company’s Series B Convertible Preferred shares are excluded from the computation of diluted earnings per share as they are anti-dilutive due to the Company’s operating losses for the years ended August 31, 2021 and 2020.
Dividends	During the year ended August 31, 2018, the Company issued Series A Convertible Preferred Stock, which accrues dividends at a rate of 5% annually. As discussed on Note 4 - Exchange Agreement	During the year ended August 31, 2018, the Company issued Series A Convertible Preferred Stock, which accrues dividends at a rate of 5% annually. As discussed on Note 3 – Exchange Agreement
Advertising Costs	The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising costs totaling $156 and $210 during the three months ended November 30, 2021 and 2020, respectively.	The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising costs totaling $677 and $2,664 during the years ended August 31, 2021 and 2020, respectively.
Stock-Based Compensation	The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. There was $-0- stock-based compensation during three months ended November 30, 2021 and 2020.	The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. There was $-0- stock-based compensation during years ended August 31, 2021 and 2020.
Related Parties	The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.	The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Recently Issued Accounting Standards	In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06 , Derivatives and Hedging Derivatives and Hedging-Contracts in Entity’s Own Equity Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company.	In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06 , Derivatives and Hedging Derivatives and Hedging—Contracts in Entity’s Own Equity Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company.
Accounts Receivable	Accounts receivable balances are established for amounts owed to the Company from its customers from the sale of products. The Company closely monitors the collectability of outstanding accounts receivable and provide an allowance for doubtful accounts based on estimated collections of outstanding amounts. The Company evaluated the accounts receivable and determined no collection loss reserve was necessary. There were $-0- outstanding accounts receivable as of November 30, 2021 and August 31, 2021.	Accounts receivable balances are established for amounts owed to the Company from its customers from the sale of products. The Company closely monitors the collectability of outstanding accounts receivable and provide an allowance for doubtful accounts based on estimated collections of outstanding amounts. The Company evaluated the accounts receivable and determined no collection loss reserve was necessary. There were $-0- outstanding accounts receivable as of August 31, 2021 and 2020.
Trademark	Trademark costs are capitalized as incurred to the extent the Company expects the costs incurred to result in a trademark being awarded. The trademarks are deemed to have an indefinite life and are reviewed for impairment loss considerations annually. As of November 30, 2021 and August 31, 2021, the Company had trademarks totaling $1,680.	Trademark costs are capitalized as incurred to the extent the Company expects the costs incurred to result in a trademark being awarded. The trademarks are deemed to have an indefinite life and are reviewed for impairment loss considerations annually. As of August 31, 2021 and 2020, the Company had trademarks totaling $1,680.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of Property, Plant and Equipment, estimated useful lives	Estimated Useful Lives Computer and other equipment 3 years Vehicle 5 years	Estimated Useful Lives Computer and other equipment 3 years Vehicle 5 years
Schedule of Property, Plant and Equipment	November 30, 2021 August 31, 2021 Computer Equipment $ -0- $ 1,569 Other -0- 3,587 Accumulated depreciation -0- (4,558 ) Net book value $ -0- $ 598	August 31, 2021 August 31, 2020 Computer Equipment $ 1,569 $ 1,569 Other 3,587 3,587 Accumulated depreciation (4,558 ) (3,144 ) Net book value $ 598 $ 2,012
Schedule of inventories	Type November 30, 2021 August 31, 2021 Raw Materials $ -0- $ -0- T-free Distillate -0- 17,000 Total Inventory $ -0- $ 17,000	Type August 31, 2021 August 31, 2020 Raw Materials $ -0- $ 450 T-free Distillate 17,000 37,000 Total Inventory $ 17,000 $ 37,450

ASSET ACQUISITION (Tables)

ASSET ACQUISITION (Tables)	3 Months Ended
	Nov. 30, 2021
ASSET ACQUISITION
Schedule of fair value of assets and liabilities	Mioxal® $ 81,249,827 Other intangible assets 178,000 Less liabilities assumed: Mioxal® liability assumed 39,500,000 Other liabilities assumed 423,000 Convertible note payable to the Company 500,000 Net fair value acquired in asset acquisition $ 41,004,827

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	12 Months Ended
	Aug. 31, 2021
DERIVATIVE LIABILITY
Summarizes of stock option activity	Warrants Weighted- Average Exercise Price Per Share Outstanding, August 31, 2020 27,532 $ 50.82 Granted - - Exercised - - Forfeited - - Cancelled (27,532 ) (50.82 ) Outstanding, August 31, 2021 - $ -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Aug. 31, 2021
INCOME TAXES
Federal income tax rate	2021 2020 Income tax provision at the federal statutory rate 21 % 21 % Effect on operating losses (21 %) (21 %)
Schedule of deferred tax assets	August 31, 2021 August 31, 2020 Deferred tax asset $ 615,839 $ 807,225 Valuation allowance (615,839 ) (807,225 ) Net deferred tax asset $ - $ -

RESTATEMENT (Tables)

RESTATEMENT (Tables)	3 Months Ended
	Nov. 30, 2021
RESTATEMENT
Schedule of changes to consolidated statements of cash flow	For the Three Months Ended Restated Previous November 30, November 30, 2021 2021 Change Cash flows from investing activities: Cash paid for asset purchase (350,000 ) (850,000 ) 500,000 Notes receivable investment (500,000 ) - (500,000 ) Net cash used in investing activities (850,000 ) (850,000 ) -

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)1 - USD ($)	Oct. 10, 2017	Oct. 09, 2017
Formulation in common stock		105,519
My Cloudz [Member] | Reverse Merger [Member]
Business acquisition, common stock, shares received	227,273
Business acquisition, common shares issued and outstanding, Percentage	57.00%
Business acquisition, cash balance	$ 3,972
Business acquisition, accounts payable	1,105
Business acquisition, related party payable	$ 75,907

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended	12 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
Computer and other equipment [Member]
Property and equipment, estimated useful life	3 years	3 years
Vehicles [Member]
Property and equipment, estimated useful life	5 years	5 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Net book value	$ 0	$ 598	$ 2,012
Accumulated depreciation	0	(4,558)	(3,144)
Computer Equipment [Member]
Property and equipment	0	1,569	1,569
Other [Member]
Property and equipment	$ 0	$ 3,587	$ 3,587

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Inventory	$ 0	$ 17,000	$ 37,450
T-Free Distillate [Member]
Inventory	0	17,000	37,000
Raw Materials [Member]
Inventory	$ 0	$ 0	$ 450

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2018	Apr. 09, 2021	Aug. 31, 2019
Obsolete Inventory, written off	$ 17,000	$ 0	$ 19,450	$ 485,662
Cash	2,933,712	29,550	137,476	17,881			$ 18,975
Depreciation	0	430	1,414	2,613
Dividends payable	275,082		138,195	73,995		$ 2,588,869
Advertising costs	$ 156	210	$ 677	2,664
Common stock shares outstanding	20,020,239		188,616
Stock based compensation	$ 0	$ 0	$ 0		$ 0
Outstanding accounts receivable			0	0
Series B-1 stock subscriptions increased	2,976,236
Derivative liability	0		0	1,454,480			$ 1,454,480
Trademarks	$ 1,680		$ 1,680	$ 1,680
Preferred stock Series A [Member]
Dividend rate, percentage					5.00%
Preferred stock Series B [Member]
Common stock issued upon conversion of preferred stock	8,083,542		2,694,514
Dividend rate, percentage			10.00%

ASSET ACQUISITION (Details)

ASSET ACQUISITION (Details)	Nov. 05, 2021USD ($)
ASSET ACQUISITION
Mioxal?	$ 81,249,827
Other intangible assets	178,000
Less liabilities assumed
Mioxal? liability assumed	39,500,000
Other liabilities assumed	423,000
Convertible note payable to the Company	500,000
Net fair value acquired in asset acquisition	$ 41,004,827

ASSET ACQUISITION (Details Narr

ASSET ACQUISITION (Details Narrative) - USD ($)	Nov. 09, 2021	Nov. 09, 2021	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Amount received	$ 15,000,000	$ 15,000,000
Intangible assets	$ 178,000
Useful life asset	21 years
Amortization	$ 8,476
Cash consideration paid	$ 39,500,000	$ 39,500,000
Interest on royalty,percentage	8.00%
Common stock value per share			$ 0.001	$ 0.001	$ 0.001
Common stock value			$ 20,020	$ 188	$ 187
Common stock shares issued	555,556	555,556	20,020,239	188,616	187,194
Debt discount	$ 55,556
Mioxal [Member]
Useful life asset	24 years
Amortization	$ 3,385,409
S T Bio Sciences Ltd [Member]
Cash consideration paid	$ 350,000	$ 350,000
Common stock value per share	$ 2.05	$ 2.05
Common stock value	$ 40,654,827	$ 40,654,827
Common stock shares issued	19,831,623	19,831,623
Debt discount	$ 500,000	$ 55,556
Common Stock fully diluted aggregate fair value	$ 41,004,827	41,004,827
Shares acquired	19,831,623
S T Bio Sciences Ltd [Member] | Tranche One [Member]
Amount received	$ 4,000,000	4,000,000
S T Bio Sciences Ltd [Member] | Tranche Two [Member]
Amount received	5,000,000	5,000,000
S T Bio Sciences Ltd [Member] | Tranche Three [Member] | September 10, 2024 [Member]
Amount received	6,000,000	6,000,000
Ingenius Biotech [Member]
Current and long-term liabilities	39,500,000	39,500,000
Ingenius Biotech [Member] | January 15, 2022 [Member]
Asset acquisition first installment	1,500,000	1,500,000
Asset acquisition thereafter	3,500,000	3,500,000
Asset acquisition aggregate amount	24,500,000	24,500,000
Additional liabilities assumed	423,000	423,000
Ingenius Biotech [Member] | April 15, 2022 [Member]
Asset acquisition second installment	$ 1,500,000	$ 1,500,000

EXCHANGE AGREEMENT (Details Nar

EXCHANGE AGREEMENT (Details Narrative) - USD ($)	Apr. 09, 2021	May 17, 2019	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Dividend payable, total	$ 2,588,869		$ 275,082	$ 138,195	$ 73,995
Series B Convertible Preferred Shares [Member]
Total Designated Shares			2,694,514	2,694,514
Stated value per share			$ 1.30	$ 1.30
Rate of interest			10.00%	10.00%
Debt instrument conversion price description			conversion price, which is (i) $1.30 or (ii) 75% of the price paid per share by investors in any subsequent offering of the Company’s common stock or common stock equivalents, subject to adjustment as provided herein, subject to adjustment as set forth below (the “Conversion Price”)	conversion price, which is (i) $1.30 or (ii) 75% of the price paid per share by investors in any subsequent offering of the Company’s common stock or common stock equivalents, subject to adjustment as provided herein, subject to adjustment as set forth below (the “Conversion Price”)
Percentage of stock converted			4.99%	4.99%
Series A Convertible Preferred Shares [Member]
Dividend payable, total	105,432
Preferred stock aggregate value	$ 1,006,000
Calvary Fund Management, LLC [Member]
Total Designated Shares	2,694,514
Description of shares exchange agreement	it agreed to issue Calvary 2,694,514 shares of its newly designated Series B Convertible Preferred Stock (the “Series B Preferred”) in exchange (the “Exchange”) for (i) 8,480,000 shares of its Series A Convertible Preferred Stock (the “Series A Preferred”), (ii) outstanding common stock purchase warrants (the “Warrants”), and (iii) all principal and accrued interest due under outstanding convertible promissory notes (the “Convertible Notes”, and together with the Series A Preferred and the Warrants, the “Calvary Securities”)
Interest on notes payable	$ 1,477,437
Calvary Fund Management, LLC [Member] | Series B Convertible Preferred Stock [Member]
Preffered stock, Ownership percentage			5.00%	5.00%
Pinz Capital Special Opportunities Fund LP [Member] | Series A Convertible Preferred Shares [Member]
Preferred stock acquired		2,107,356
Acqusition of preferred stock warrant		2,107,356

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020
GOING CONCERN
Net operating income (loss)	$ (361,072)	$ (57,175)	$ (238,991)	$ (216,877)
Accumulated deficit	$ (3,350,368)		$ (2,973,628)	$ (3,843,927)

NOTES RECEIVABLE (Details Narra

NOTES RECEIVABLE (Details Narrative) - USD ($)	Nov. 09, 2021	Nov. 09, 2021	Apr. 29, 2020	Apr. 27, 2020	Jan. 24, 2020	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020
Equity investment, net of discount						$ 0		$ 11,132	$ 2,783
Promissory note								150,000
Other income						$ 1,583	$ 2,087	$ 8,349	$ 8,349
Debt discount	$ 55,556
Common stock par value						$ 0.001		$ 0.001	$ 0.001
Note receivable								$ 0	$ 132,852
NGBL [Member]
Promissory note					$ 112,500
Notes receivable, interest rate					12.50%
Notes receivable, discount on issue, percentage					12.50%
Notes receivable, payment, description					once the promissory note has been repaid, the Company shall be paid an aggregate of 3.75% of the 2020 derivative products revenues sold by the supplier
Impairment charge								100,000
Libertas Participation Agreement [Member] | QSI Holding Company [Member]
Common stock issuable upon exercise of warrants			45,053	45,053
Purchase Common Stock price per share			$ 3.111	$ 3.111
Common stock issuable upon exercise of warrants, value			$ 58,443	$ 58,443
Exercise price			$ 3.111	$ 3.111
Risk-free rate			0.56%	0.56%
Volatility			32.00%	32.00%
Common stock par value			$ 0.00001	$ 0.00001
Warranty life in years			7 years	7 years
Debt/stock based issue costs			$ 58,443	$ 58,443
Value per common share			$ 3.4520	$ 3.4520
Participation Agreement [Member] | Libertas Funding, LLC [Member] | Connecticut Limited Liability Company [Member]
Participation buy-in, amount				$ 200,000
Participation purchase, amount				$ 264,000
Note receivable								200,000
Participation purchase, unpaid balance								0	$ 132,852
September 1, 2020 [Member]
Previous negotiated weekly payment								6,984
Renegotiated weekly payment receivables								$ 4,921
S T Bio Sciences Ltd [Member]
Debt discount	500,000	$ 55,556
Note issued	$ 555,556	$ 555,556
Interest rate		6.00%
Offering price		70.00%
Minimum gross proceeds		$ 6,000,000
Common stock par value	$ 2.05	$ 2.05

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Nov. 09, 2021	Sep. 14, 2017	Jun. 15, 2020	Apr. 27, 2020	Jan. 27, 2020	Nov. 25, 2019	Aug. 27, 2019	May 31, 2018	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2019
Debt instrument, interest payable									$ 0	$ 80,512	$ 114,599	$ 869,967
Interest expenses									5,139	36,750
Note payable, convertible net of discount											0	831,170
Convertible notes payable							$ 30,000
Debt discount	$ 55,556
Short-Term Notes Payable 1 [Member]
Unpaid accrued interest									0		$ 150,074
Debt instrument, maturity date								Nov. 30, 2018			Aug. 30, 2021
Promisory notes payable								$ 39,500			$ 150,000
Notes payable, interest rate								0.00%			18.00%
Short-Term Debts [Member]
Debt instrument, maturity date		Sep. 15, 2018
Promisory notes payable		$ 10,000
Notes payable, interest rate		5.00%
Accrued interest									12,107		$ 11,982	11,482
Convertible Promissory Notes 4 [Member]
Convertible notes payable						$ 140,000
Debt instrument, discount						$ 14,000
Unpaid accrued interest											0	212,577
Notes payable description						If in default, the payment premium increases to 140% of the principal and interest outstanding
Debt instrument, interest rate, percentage						10.00%
Debt instrument, payment, description						The note has a prepayment penalty of 110% of the principal and interest outstanding if repaid before 180 days from issuance
Debt Instrument, notice period, Description						the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company
Debt instrument, conversion rate, percentage						35.00%
Convertible Promissory Note [Member] | Investor [Member]
Convertible notes payable				$ 259,615	$ 555,000
Unpaid accrued interest									0		0	825,475
Debt instrument, payment, description				The note requires nine equal payments due starting June 15, 2020 for $28,846. In the event the Company fails to make the $28,846 installment payment by the 15th day of each designated month and/or fails to cure any missed installment payment within five (5) calendars days following the due date, or the Company defaults, the defaulted amount owed shall be 130% of the total outstanding balance owed by the Company	The note has a prepayment penalty of 115% of the principal and interest outstanding
Debt dafault condition, description				The default interest rate for missing an installment payment shall be 18% and the conversion into common stock shall be at a price of $0.02 per common stock
Loan payable				$ 202,500
Accrued interest				57,115
Debt instrument, discount				$ 57,115	$ 55,500				0
Debt instrument, interest rate, percentage				0.00%	10.00%
Installment payment			$ 28,846
Conversion description				The note principal and interest are convertible into shares of common stock at the lower of $0.02 per share or a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company
Debt instrument, maturity date				Feb. 21, 2021
Unpaid principle balance									0		0	287,665
Convertible Promissory Note 1 [Member]
Interest expenses									5,139	36,750
Convertible notes payable							30,000
Debt instrument, discount							$ 3,000		0	80,511
Unpaid accrued interest											$ 0	$ 46,870
Notes payable description							After February 27, 2020, the payment premium increases to 125% of the principal and interest outstanding and if in default, the payment premium increases to 140% of the principal and interest outstanding
Debt instrument, interest rate, percentage							10.00%
Debt instrument, payment, description							The note has a prepayment penalty of 110% of the principal and interest outstanding if repaid before 180 days from issuance
Debt Instrument, notice period, Description							the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company
Debt instrument, conversion rate, percentage							25.00%
Debt instrument, discount													$ 27,000
Debt instrument, maturity date							Feb. 27, 2020
Debt discount									$ 0	$ 80,511

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Nov. 30, 2021	Aug. 31, 2021	Aug. 31, 2020
Due to related party	$ 0	$ 64,600	$ 73,469
President And Director [Member]
Due to related party	$ 0	$ 64,600	$ 73,469

STOCKHOLDERS EQUITY (Details Na

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Nov. 24, 2021	Nov. 09, 2021	Oct. 28, 2021	Sep. 07, 2021	Jan. 28, 2020	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020
Common stock par value						$ 0.001		$ 0.001	$ 0.001
Common stock, shares authorized						200,000,000		200,000,000	200,000,000
Common stock, shares issued		555,556				20,020,239		188,616	187,194
Common stock, shares outstanding						20,020,239		188,616	187,194
Restricted shares of common stock					252,833
Common stock shares, issuable value					$ 80,000
Aggregate gross proceeds						$ 0	$ 1,659	$ 1,659	$ (1,783)
STB [Member]
Gross proceeds		$ 40,654,827
Shares Issued		19,831,623
Convertible Preferred Stock A [Member]
Preferred stock, shares issued						0		0	8,480,000
Preferred stock, shares outstanding						0		0	8,480,000
Convertible Preferred Stock B [Member]
Preferred stock, shares issued						8,083,542		2,694,514	0
Preferred stock, shares outstanding						8,083,542		2,694,514	0
Preferred stock, shares designated						2,694,514		2,694,514
L1 Capital [Member]
Gross proceeds	$ 2,000,000
Aggregate gross proceeds	$ 2,000,000
L1 Capital [Member] | Series B1 Convertible Preferred Stock [Member]
Gross proceeds				$ 500,000
Shares Issued				673,628
L1 Capital [Member] | Initial Tranche [Member]
Gross proceeds				$ 2,000,000
Shares Issued				2,694,514
L1 Capital [Member] | Tranche Two [Member]
Gross proceeds			$ 500,000
Shares Issued			673,628
L1 Capital [Member] | Tranche Three [Member]
Gross proceeds		$ 1,000,000
Shares Issued		1,347,256
Aggregate gross proceeds		$ 2,000,000

DERIVATIVE LIABILITY (Details)

DERIVATIVE LIABILITY (Details) - Warrants [Member]	12 Months Ended
	Aug. 31, 2021$ / sharesshares
Number of warrants/rights, Outstanding, August 31, 2020 | shares	27,532
Number of warrants/rights, Cancelled | shares	(27,532)
Weighted Average Exercise Price Per Share, Outstanding, August 31, 2020	$ 50.82
Weighted Average Exercise Price Per Share, Granted	0
Weighted Average Exercise Price Per Share, Exercised	0
Weighted Average Exercise Price Per Share, Forfeited	0
Weighted Average Exercise Price Per Share, Cancelled	(50.82)
Weighted Average Exercise Price Per Share, Outstanding, August 31, 2021	$ 0

DERIVATIVE LIABILITY (Details N

DERIVATIVE LIABILITY (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended			12 Months Ended
	Apr. 27, 2020	Jan. 27, 2020	Nov. 25, 2019	Aug. 27, 2019	Nov. 30, 2021	Nov. 30, 2020	Feb. 29, 2020	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2019
Interest accretion					$ 0	$ 80,512		$ 114,599	$ 869,967
Convertible notes payable				$ 30,000
Change in fair value of derivative liabilities					0			(1,454,480)	(301,581)
Discount on conversion into common stock				0.25%
Derivative liability					0			$ 0	1,454,480	$ 1,454,480
Derivative liability description								The Company used the following assumptions upon measurement: value per common share of $2.25, a remaining life of 1 month, an exercise price of $1.66, a risk-free rate of .04% and volatility of 162%.
Net income (loss)					(239,853)	(237,268)		$ 1,039,932	$ (2,580,068)
Monte Carlo Simulation Model [Member]
Derivative liability					587,772		$ 929,300	587,772
Debt instrument, discount					$ 57,115		$ 55,500	$ 57,115
Life of debt instrument					9 years		6 years	9 years
Expected volatility rate					304.00%		2.81%	3.04%
Exercise price					$ 1.28		$ 3.13	$ 1.28
Risk-free interest rate					0.17%		1.57%	0.17%
Value per common share					$ 3.17		$ 6.65	$ 3.17
Loss on issuance of debt					$ 385,272		$ 429,800	$ 385,272
Total Discount on debt					259,615		555,000	259,615
Derivative discount					202,500		$ 499,500	202,500
Derivative Liability Summary [Member]
Change in fair value of derivative liabilities								$ (301,581)
Derivatives liability [Member]
Expected volatility rate								2.65%
Exercise price								$ 50.82
Expected term (in years)								7 months 28 days
Risk-free interest rate								0.05%
Derivatives [Member] | August 31, 2018 [Member]
Expected volatility rate								1.95%
Exercise price								$ 50.82
Value per common share								$ 27.72
Expected term (in years)								3 years
Risk-free interest rate								2.77%
Detachable warrants								27,532
Exercisable period								3 years
Debt/stock based issue costs								$ 674,012
Investor [Member]
Conversion description		The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company
Convertible promissory note		$ 555,000
Convertible Promissory Note [Member] | Investor [Member]
Convertible notes payable	$ 259,615	555,000
Conversion description	The note principal and interest are convertible into shares of common stock at a 25% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day
Derivative discount	$ 57,115	$ 55,500			0
Convertible Promissory Note 1 [Member]
Convertible notes payable				$ 30,000
Derivative liability										50,277
Net income (loss)										23,277
Derivative discount										27,000
Debt instrument, discount				$ 3,000	0	$ 80,511
Debt instrument, conversion rate, percentage				25.00%
Derivative aggregated discount										30,000
Original issue discount										$ 3,000
Convertible Promissory Note 1 [Member] | Derivative liabilities [Member]
Expected volatility rate										2.87%
Exercise price										$ 1.30
Risk-free interest rate										1.98%
Value per common share										$ 2.74
Expected term (in years)										6 years
Convertible Promissory Note 2 [Member]
Derivative liability					172,608			172,608
Net income (loss)					46,608			46,608
Derivative discount					126,000			126,000
Derivative aggregated discount					140,000			140,000
Original issue discount					$ 14,000			$ 14,000
Terms of conversion feature			The note principal and interest are convertible into shares of common stock at a 35% discount to the lowest traded price of the Company’s common stock during the 10 prior trading days including the day the notice of conversion is received by the Company
Convertible promissory note payabe			$ 140,000
Convertible Promissory Note 2 [Member] | Derivative liabilities [Member]
Expected volatility rate					275.00%			2.75%
Exercise price					$ 0.93			$ 0.93
Risk-free interest rate					1.61%			1.61%
Value per common share					$ 1.54			$ 1.54
Expected term (in years)					6 years			6 years

MATERIAL CONTRACTS (Details Nar

MATERIAL CONTRACTS (Details Narrative) - USD ($)	1 Months Ended						12 Months Ended
	Feb. 29, 2020	Jan. 31, 2020	Jan. 24, 2020	Dec. 13, 2019	Nov. 27, 2019	Oct. 31, 2019	Aug. 31, 2020	Nov. 30, 2021	Aug. 31, 2021	Jun. 01, 2021
Equity investment method							$ 2,783	$ 0	$ 11,132
Non-binding letter of intent [Member] | NanoPeak Performances, LLC [Member]
Non-rerfundable deposits received	$ 25,000					$ 25,000
Non-rerfundable deposits received, written off							25,000
Contract fullfillment expenses							72,500
Purchase of industrial hemp (biomass)		30000 pounds
Industrial hemp (biomass), price per unit		$ 5
Industrial hemp (biomass), Total amount		$ 150,000
Toll Processing Agreement [Member]
Contract price				$ 100,000
NGBL [Member] | Collaboration Agreement [Member]
Equity investment method			$ 250,000
Fair value of NGBL shares										$ 0
Ownership percentage			20.00%
Description of agreement termination period			Either party may terminate this agreement at any time upon 10 business days’ written notice
Industrial Hemp (biomass) [Member]
Contract price					$ 100,000
Supply agreement with grower to purchase description					the Company signed a Supply Agreement with Notis Global, Inc. (“NGBL”), a grower to purchase 10,000 pounds of industrial hemp (biomass) and was processed into crude during the three months ended May 31, 2020
Obsolete Inventory, written off							115,000
Wrote down of raw material									$ 19,100
Fair market value							$ 35,000

INCOME TAXES (Details)

INCOME TAXES (Details)	12 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
INCOME TAXES
Income tax provision at the federal statutory rate	21.00%	21.00%
Effect on operating losses	(21.00%)	(21.00%)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Aug. 31, 2021	Aug. 31, 2020
INCOME TAXES
Deferred tax asset	$ 615,839	$ 807,225
Valuation allowance	(615,839)	(807,225)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	12 Months Ended
	Aug. 31, 2021USD ($)
INCOME TAXES
Change in valuation allowance	$ 191,836
Income tax rate reduction description	The U.S. Tax Cuts and Jobs Act (TCJA) legislation reduces the U.S. federal corporate income tax rate from 35.0% to 21.0% and is effective June 22, 2018 for the Company

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jan. 13, 2022	Nov. 24, 2021	Nov. 09, 2021	Oct. 28, 2021	Sep. 07, 2021	Dec. 31, 2022	Jun. 30, 2022
STB [Member]
Gross proceeds			$ 40,654,827
Calvary Fund One Lp [Member] | Series B1 Convertible Preferred Stocks [Member]
Share price		$ 0.742245
Share issued		2,694,514
Gross proceeds		$ 2,000,000
Calvary Fund One Lp [Member] | STB [Member]
Share issued			19,831,623		673,628
L1 Capital [Member]
Warrant to common stock			45,053
Exercise price			$ 3.1336
Debt forgiveness			$ 150,000
Share price			$ 0.00001
Gross proceeds		$ 2,000,000
L1 Capital [Member] | Tranche Three [Member]
Gross proceeds			$ 1,000,000
L1 Capital [Member] | Tranche Two [Member]
Gross proceeds				$ 500,000
L1 Capital [Member] | Initial Tranche [Member]
Gross proceeds					$ 2,000,000
L1 Capital [Member] | Calvary Fund One Lp [Member] | Initial Tranche [Member]
Share issued					2,694,514
Gross proceeds					$ 2,000,000
Series B-1, Preferred Stock | Calvary Fund One Lp [Member] | Tranche Three [Member]
Share price			$ 0.742245
Share issued			1,347,256
Gross proceeds			$ 1,000,000
Series B-1, Preferred Stock | Calvary Fund One Lp [Member] | Tranche One [Member]
Share price					$ 0.742245
Share issued					637,628
Gross proceeds					$ 500,000
Series B-1, Preferred Stock | Calvary Fund One Lp [Member] | Tranche Two [Member]
Share price				$ 0.742245
Share issued				637,628
Gross proceeds				$ 500,000
Subsequent Event [Member]
Closing Consideration of the purchase agreement	$ 150,000					$ 1,500,000	$ 1,500,000

RESTATEMENT (Details)

RESTATEMENT (Details) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Aug. 31, 2021	Aug. 31, 2020
Notes receivable investment	$ (500,000)	$ 0	$ 0	$ (300,000)
Net cash used in investing activities	(850,000)	$ 0	$ 0	$ (380,000)
Restated [Member]
Cash paid for asset purchase	(350,000)
Notes receivable investment	(500,000)
Net cash used in investing activities	(850,000)
Previous [Member]
Cash paid for asset purchase	(850,000)
Notes receivable investment	0
Net cash used in investing activities	(850,000)
Change [Member]
Cash paid for asset purchase	500,000
Notes receivable investment	(500,000)
Net cash used in investing activities	$ 0